市場調査レポート
商品コード
1459084

体外診断の世界市場 :製品&サービス別、技術別、検体別、製品タイプ別、用途別 - 予測(~2029年)

In Vitro Diagnostics Market by Product & Service (Instruments, Kits, Software), Technology (Immunoassay, Hematology, Urinalysis), Specimen (Blood, Saliva), Test Type, Application (Oncology, Autoimmune, CVD, Infectious Diseases) - Global Forecast to 2029

出版日: | 発行: MarketsandMarkets | ページ情報: 英文 677 Pages | 納期: 即納可能 即納可能とは

● お客様のご希望に応じて、既存データの加工や未掲載情報(例:国別セグメント)の追加などの対応が可能です。  詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=156.58円
体外診断の世界市場 :製品&サービス別、技術別、検体別、製品タイプ別、用途別 - 予測(~2029年)
出版日: 2024年03月27日
発行: MarketsandMarkets
ページ情報: 英文 677 Pages
納期: 即納可能 即納可能とは
  • 全表示
  • 概要
  • 目次
概要

世界の体外診断の市場規模は、予測期間中に6.9%のCAGRで推移し、2024年の852億米ドルから、2029年には1,194億米ドルの規模に成長すると予測されています。

世界の老齢人口の急増に伴い、加齢に伴う疾患の有病率が大幅に増加すると予想されています。糖尿病、癌、心血管疾患を含む慢性疾患は、老年期に多く見られます。これらの疾患は継続的に監視・管理する必要があるため、診断検査の必要性が高まっています。また、免疫力の低下により、感染症にもかかりやすくなっています。感染症の効果的な治療は、体外診断検査によって可能になる早期発見にかかっています。したがって、これらの要因が体外診断市場の成長を大きく促進しています。

調査範囲
調査対象年 2021-2029年
基準年 2023年
予測期間 2024-2029年
単位 金額 (米ドル)
セグメント 製品&サービス・検体・技術・検査タイプ・用途・エンドユーザー
対象地域 北米・欧州・アジア太平洋・ラテンアメリカ・中東&アフリカ・GCC諸国

技術別では、分子診断の部門が予測期間中にもっとも高い成長率を示すと予測されています。同部門の成長は、感染症、癌、さまざまな遺伝性疾患の有病率の上昇、血液スクリーニングの需要拡大、薬理遺伝学およびポイントオブケア検査における分子診断技術の使用の拡大が主な要因です。

用途別では、内分泌の部門が予測期間中にもっとも高い成長率を示すと予測されています。技術の進歩、糖尿病や甲状腺疾患の罹患率の増加、ライフスタイルの変化、これらの病状をコントロールするための在宅検査のアベイラビリティなどが、内分泌用途の成長の主な促進要因です。

地域別では、アジア太平洋地域が予測期間中にもっとも高い成長率を示すと予測されています。医療支出の増加、老齢人口の急増、可処分所得の増加により、この地域は成長機会として有利な市場となっています。

当レポートでは、世界の体外診断の市場を調査し、市場概要、市場影響因子および市場機会の分析、技術・特許の動向、法規制環境、市場規模の推移・予測、各種区分・地域別の詳細分析、競合情勢、主要企業のプロファイルなどをまとめています。

目次

第1章 イントロダクション

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 重要考察

第5章 市場概要

  • 市場力学
    • 促進要因
    • 抑制要因
    • 機会
    • 課題
  • 価格分析
  • バリューチェーン分析
  • サプライチェーン分析
  • ポーターのファイブフォース分析
  • エコシステム分析
  • 規制機関、政府機関、その他の組織
  • 規制分析
  • 特許分析
  • 顧客のビジネスに影響を与える動向/ディスラプション
  • 主な会議とイベント
  • 技術分析
  • 主なステークホルダーと購入基準
  • 貿易分析

第6章 体外診断市場:製品・サービス別

  • 試薬・キット
  • 機器
  • データ管理ソフトウェア・サービス

第7章 体外診断市場:技術別

  • イムノアッセイ
    • 酵素免疫測定法 (ELISA)
    • 化学発光免疫測定
    • 免疫蛍光アッセイ
    • 迅速検査
    • 酵素結合免疫スポットアッセイ (ELISPOT)
    • ウェスタンブロッティング
    • その他
  • 臨床化学
    • 基礎代謝パネル
    • 肝臓パネル
    • 腎臓プロファイル
    • 脂質プロファイル
    • 甲状腺機能パネル
    • 電解質パネル
    • 特殊化学試験
  • 分子診断
    • ポリメラーゼ連鎖反応 (PCR)
    • 等温核酸増幅技術 (INAAT)
    • DNAシーケンシング・次世代シーケンシング (NGS)
    • インサイチュハイブリダイゼーション (ISH)
    • DNAマイクロアレイ
    • その他
  • 血液学
  • 微生物学
  • 凝固・止血
  • 尿検査
  • クロマトグラフィー・質量分析

第8章 体外診断市場:検体別

  • 血液、血清、血漿
  • 唾液
  • 尿
  • その他

第9章 体外診断市場:検査タイプ別

  • 臨床検査
  • ポイントオブケア検査

第10章 体外診断市場:用途別

  • 感染症
  • 腫瘍
  • 内分泌
  • 心臓病
  • 血液検査
  • 遺伝子検査
  • 自己免疫疾患
  • アレルギー診断
  • 薬物モニタリング・検査
  • 骨・ミネラル障害
  • 凝固検査
  • 血液型判定
  • その他

第11章 体外診断市場:エンドユーザー別

  • 病院・クリニック
  • 臨床ラボ
    • 大規模リファレンスラボ
    • 中小規模ラボ
  • 血液バンク
  • 在宅ケア
  • 製薬・バイオ技術企業
  • 学術機関
  • その他

第12章 体外診断市場:地域別

  • 北米
  • 欧州
  • アジア太平洋
  • ラテンアメリカ
  • 中東・アフリカ
  • GCC諸国

第13章 競合情勢

  • 概要
  • 主要企業の採用戦略
  • 主要企業の収益シェア分析
  • 市場シェア分析
  • 企業評価マトリックス:主要企業
  • スタートアップ/中小企業評価マトリックス
  • 競合シナリオ
  • ブランド/製品比較

第14章 企業プロファイル

  • 主要企業
    • DANAHER CORPORATION
    • ROCHE DIAGNOSTICS
    • ABBOTT
    • SIEMENS HEALTHINEERS AG
    • THERMO FISHER SCIENTIFIC INC.
    • ILLUMINA, INC.
    • HOLOGIC, INC.
    • BIO-RAD LABORATORIES, INC.
    • BIOMERIEUX
    • SYSMEX CORPORATION
    • REVVITY
    • BECTON, DICKINSON AND COMPANY
    • AGILENT TECHNOLOGIES, INC.
    • QIAGEN N.V.
    • DIASORIN S.P.A.
    • GRIFOLS S.A
    • WERFEN S.A.
    • QUIDELORTHO CORPORATION
  • その他の企業
    • DEVYSER
    • CHEMBIO DIAGNOSTICS, INC.
    • SURMODICS, INC.
    • MENARINI SILICON BIOSYSTEMS
    • SPEEDX PTY. LTD.
    • GENSPEED BIOTECH GMBH
    • MERCK KGAA
    • CARIS LIFE SCIENCES, INC.
    • ARKRAY, INC.
    • ACCELERATE DIAGNOSTICS, INC.
    • CELLABS
    • J. MITRA & CO. PVT. LTD.
    • EPITOPE DIAGNOSTICS, INC.
    • BOSTER BIOLOGICAL TECHNOLOGY
    • ENZO BIOCHEM, INC.
    • GENETIC SIGNATURES
    • SAVYON DIAGNOSTICS LTD.
    • TRIVITRON HEALTHCARE
    • MDXHEALTH SA
    • CREATIVE DIAGNOSTICS
    • INBIOS INTERNATIONAL, INC.
    • MACCURA BIOTECHNOLOGY CO., LTD.
    • VELA DIAGNOSTICS

第15章 付録

目次
Product Code: MD 3609

The global in vitro diagnostics market is projected to reach USD 119.4 billion by 2029 from USD 85.2 billion in 2024, at a CAGR of 6.9% during the forecast period. With the rapid growth in the geriatric population globally, the prevalence of age-associated diseases is expected to increase significantly. Chronic conditions that include diabetes, cancer, and cardiovascular disease are more common in old age. As these diseases need to be continuously monitored and managed, there is an increasing need for diagnostic tests. Also, due to a weakened immune system, people get increasingly susceptible to several infectious diseases. Effective treatment of infectious diseases depends on early detection, which made possible by IVD tests. Hence, this factor is significantly inducing growth of the IVD market.

Scope of the Report
Years Considered for the Study2021-2029
Base Year2023
Forecast Period2024-2029
Units ConsideredValue (USD) Billion
SegmentsProduct & Service, Specimen, Technology, Test Type, Application, and End User
Regions coveredNorth America, Europe, Asia Pacific, Latin America, Middle East & Africa, and GCC Countries

"Molecular diagnostics (MDx) segment is projected to witness highest growth rate in the in vitro diagnostics market, by technology, during the forecast period."

Based on the technology the IVD market is bifurcated into immunoassays, clinical chemistry, molecular diagnostics, hematology, microbiology, coagulation & hemostasis, urinalysis, and chromatography & mass spectrometry. The molecular diagnostics (MDx) segment is estimated to register the highest growth rate during the forecast period. Growth in this market is majorly driven by the rising prevalence of infectious diseases, cancer, and various genetic disorders; growing demand for blood screening; and increasing applications of molecular diagnostic technologies in pharmacogenetics and point-of-care testing.

"Endocrinology segment is projected to register highest growth rate in the in vitro diagnostics market, by application, during the forecast period."

The IVD market is bifurcated into infectious diseases, oncology, endocrinology, cardiology, blood screening, genetic testing, autoimmune diseases, allergy diagnostics, drug monitoring & testing, bone & mineral disorders, coagulation testing, blood group typing, and other applications. The endocrinology segment is expected to grow at the highest rate within the in vitro diagnostics market. Technological advancements, the increasing incidence of diabetes and thyroid disorders, changing lifestyles, and the availability of home tests to control these medical conditions are the major drivers for the growth of the IVD market for endocrinology applications.

"Asia Pacific: The fastest-growing region in vitro diagnostics market."

The global IVD market is segmented into North America, Europe, the Asia Pacific, Latin America, the Middle East & Africa, and GCC Countries. The Asia Pacific market is estimated to witness the highest growth rate during the forecast period. The rising healthcare spending, rapidly growing geriatric populations, and increasing disposable income make this region a lucrative market for growth opportunities.

The break-up of the profile of primary participants in the IVD market:

  • By Company Type: Tier 1 - 42%, Tier 2 - 30%, and Tier 3 - 28%
  • By Designation: C-level - 46%, D-level - 23%, and Others - 31%
  • By Region: North America - 23%, Europe - 45%, Asia Pacific - 28.3%, Latin America- 3%, Middle East & Africa - 0.8%, GCC Countries - 1.3%

The key players in this market are Roche Diagnostics (Switzerland), Danaher Corporation (US), Abbott Laboratories (US), Siemens Healthineers (Germany), Sysmex Corporation (Japan), Thermo Fisher Scientific, Inc. (US), Becton, Dickinson and Company (US), bioMerieux SA (France), Bio-Rad Laboratories, Inc. (US), Agilent Technologies, Inc. (US), Qiagen N.V. (Netherlands), QuidelOrtho Corporation (US), DiaSorin S.p.A. (Italy), Illumina, Inc. (US), Hologic, Inc. (US), Revvity (US), Griffols (Spain), Werfen (Spain), Devyser (Sweden), Chembio Diagnostics, Inc. (US). Surmodics, Inc. (US), Menarini Silicon Biosystems (Italy), SpeeDx Pty. Ltd. (Australia), GENSPEED Biotech GmbH (Austria), Accelerate Diagnostics, Inc. (US), Merck KGaA (Germany), Caris Life Sciences, Inc (US), Cellabs (Australia), J. Mitra & Co. Pvt. Ltd. (India), Epitope Diagnostics (US), Boster Biological Technology (US), Enzo Biochem (US), Genetic Signatures (Australia), Savyon Diagnostics (Israel), Trivitron Healthcare (India), mdxhealth (Belgium), Creative Diagnostics (US), InBios International, Inc. (US), Maccura Biotechnology Co., Ltd. (China), Vela Diagnostics (Singapore), and ARKRAY, Inc. (Japan)

Research Coverage:

This research report divided the in vitro diagnostics market by test type (PoC tests and laboratory tests), by technology (molecular diagnostics, immunoassays, coagulation & hemostasis, clinical chemistry, urinalysis, chromatography & mass spectrometry, microbiology, and hematology), by product & services (instruments, reagents & kits, and data management software and services), specimen (urine, saliva, blood, serum, and plasma, and other specimens), by end user (pharmaceutical & biotechnology companies, hospital & clinics, blood banks, academic institutes, clinical laboratories, home care settings, and other end users), by application (endocrinology, cardiology, blood screening, blood group typing, autoimmune diseases, bone & mineral disorders, oncology, coagulation testing, genetic testing, infectious diseases, allergy diagnostics, drug monitoring & testing, and other applications), and by region (Latin America, the GCC Countries, Europe, Middle East & Africa, Asia Pacific, and North America)

The report's coverage includes comprehensive details about the key factors impacting the growth of the IVD market, including opportunities, challenges, opportunities, and restraints. To offer insights into their business overview, products offered, significant strategies, acquisitions and partnerships, product launches, and recent developments related to the IVD market, a thorough analysis of the major industry players has been conducted. This study examines the competitive landscape of emerging in vitro diagnostics startups.

Reasons to buy this report:

The report will help the market leaders/new entrants in this market with information on the closest approximations of the revenue numbers for the overall in vitro diagnostics market and the subsegments. This report will help stakeholders understand the competitive landscape and gain more insights to position their businesses better and to plan suitable go-to-market strategies. The report also helps stakeholders understand the pulse of the market and provides them with information on key market drivers, restraints, challenges, and opportunities.

The report provides insights on the following pointers:

  • Analysis of key drivers: (Increasing geriatric population and subsequent rise in chronic & infectious diseases, and Emergence of rapid PoC diagnostics), restraints (Unfavorable reimbursement scenario for IVD market), opportunities (Introduction of disease-specific biomarkers and tests, and Growth opportunities in emerging markets), and challenges (Operational barriers to the IVD market) influencing the growth of the in vitro diagnostics market.
  • Product Development/Innovation: Detailed insights on research & development activities, and new product launches and approvals in the in vitro diagnostics market.
  • Market Development: Comprehensive information about lucrative markets - the report analyses the in vitro diagnostics market across varied regions.
  • Market Diversification: Exhaustive information about new products, untapped geographies, recent developments, and investments in the IVD market
  • Competitive Assessment: In-depth assessment of market shares, growth strategies and service offerings of leading players like Roche Diagnostics (Switzerland), Danaher Corporation (US), Abbott Laboratories (US), Siemens Healthineers (Germany), Thermo Fisher Scientific, Inc. (US) among others in the IVD market strategies.

TABLE OF CONTENTS

1 INTRODUCTION

  • 1.1 STUDY OBJECTIVES
  • 1.2 MARKET DEFINITION
  • 1.3 INCLUSIONS & EXCLUSIONS
  • 1.4 MARKET SCOPE
    • 1.4.1 MARKETS COVERED
    • FIGURE 1 MARKET SEGMENTATION
    • 1.4.2 REGIONS COVERED
    • 1.4.3 YEARS CONSIDERED
    • 1.4.4 CURRENCY CONSIDERED
  • 1.5 MARKET STAKEHOLDERS
  • 1.6 SUMMARY OF CHANGES
    • 1.6.1 MARKET RECONCILIATION:
  • 1.7 RECESSION IMPACT

2 RESEARCH METHODOLOGY

  • 2.1 RESEARCH DATA
    • FIGURE 2 RESEARCH DESIGN
    • 2.1.1 SECONDARY RESEARCH
      • 2.1.1.1 Key data from secondary sources
    • 2.1.2 PRIMARY DATA
      • 2.1.2.1 Primary sources
      • 2.1.2.2 Key data from primary sources
      • 2.1.2.3 Key industry insights
    • FIGURE 3 BREAKDOWN OF PRIMARY INTERVIEWS: SUPPLY-SIDE AND DEMAND-SIDE PARTICIPANTS
    • FIGURE 4 BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION, AND REGION
  • 2.2 MARKET SIZE ESTIMATION
    • 2.2.1 BOTTOM-UP APPROACH
      • 2.2.1.1 Approach 1: Company revenue estimation approach
    • FIGURE 5 REVENUE SHARE ANALYSIS
    • FIGURE 6 CAGR PROJECTIONS: SUPPLY-SIDE ANALYSIS
    • FIGURE 7 IN VITRO DIAGNOSTICS MARKET: TOP-DOWN APPROACH
  • 2.3 MARKET BREAKDOWN AND DATA TRIANGULATION
    • FIGURE 8 DATA TRIANGULATION METHODOLOGY
  • 2.4 MARKET SHARE ANALYSIS
  • 2.5 STUDY ASSUMPTIONS
  • 2.6 GROWTH RATE ASSUMPTIONS
  • 2.7 RESEARCH LIMITATIONS
    • 2.7.1 METHODOLOGY-RELATED LIMITATIONS
    • 2.7.2 SCOPE-RELATED LIMITATIONS
  • 2.8 RISK ASSESSMENT
    • TABLE 1 RISK ASSESSMENT ANALYSIS
  • 2.9 RECESSION IMPACT ANALYSIS

3 EXECUTIVE SUMMARY

    • FIGURE 9 IN VITRO DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2024 VS. 2029 (USD MILLION)
    • FIGURE 10 IN VITRO DIAGNOSTICS MARKET, BY TECHNOLOGY, 2024 VS. 2029 (USD MILLION)
    • FIGURE 11 IN VITRO DIAGNOSTICS MARKET, BY SPECIMEN, 2024 VS. 2029 (USD MILLION)
    • FIGURE 12 IN VITRO DIAGNOSTICS MARKET, BY TEST TYPE, 2024 VS. 2029 (USD MILLION)
    • FIGURE 13 IN VITRO DIAGNOSTICS MARKET, BY APPLICATION, 2024 VS. 2029 (USD MILLION)
    • FIGURE 14 IN VITRO DIAGNOSTICS MARKET, BY END USER, 2024 VS. 2029 (USD MILLION)
    • FIGURE 15 GEOGRAPHIC SNAPSHOT OF IVD MARKET

4 PREMIUM INSIGHTS

  • 4.1 IN VITRO DIAGNOSTICS MARKET OVERVIEW
    • FIGURE 16 GROWING FOCUS ON EARLY DISEASE DIAGNOSIS TO DRIVE MARKET
  • 4.2 NORTH AMERICA: IN VITRO DIAGNOSTICS MARKET, BY PRODUCT & SERVICE AND COUNTRY (2023)
    • FIGURE 17 REAGENTS & KITS SEGMENT ACCOUNTED FOR LARGEST MARKET SHARE IN 2023
  • 4.3 IN VITRO DIAGNOSTICS MARKET: REGIONAL MIX
    • FIGURE 18 ASIA PACIFIC TO WITNESS HIGHEST GROWTH RATE DURING FORECAST PERIOD
  • 4.4 IN VITRO DIAGNOSTICS MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES
    • FIGURE 19 CHINA AND INDIA TO REGISTER HIGHEST CAGR DURING FORECAST PERIOD
  • 4.5 IN VITRO DIAGNOSTICS MARKET: EMERGING ECONOMIES VS. DEVELOPED ECONOMIES
    • FIGURE 20 EMERGING ECONOMIES TO REGISTER HIGHER GROWTH RATE DURING FORECAST PERIOD

5 MARKET OVERVIEW

  • 5.1 INTRODUCTION
  • 5.2 MARKET DYNAMICS
    • FIGURE 21 IN VITRO DIAGNOSTICS MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
    • 5.2.1 DRIVERS
      • 5.2.1.1 Increasing geriatric population and subsequent rise in chronic & infectious diseases
    • TABLE 2 ESTIMATED INCREASE IN GERIATRIC POPULATION, BY REGION (2022-2050)
      • 5.2.1.2 Gradual shift from centralized testing to point-of-care testing
      • 5.2.1.3 Growing awareness of early disease diagnosis in emerging economies
      • 5.2.1.4 Emergence of rapid PoC technologies and rising adoption of automated analyzers
    • TABLE 3 IN VITRO DIAGNOSTICS MARKET: PRODUCT LAUNCHES (2021-2023)
      • 5.2.1.5 Growing preference for personalized medicine
      • 5.2.1.6 Increasing funding for R&D activities
    • 5.2.2 RESTRAINTS
      • 5.2.2.1 Unfavorable reimbursements
      • 5.2.2.2 Stringent regulatory requirements
    • FIGURE 22 IVDR: CRITICAL AREAS OF IMPACT
      • 5.2.2.3 High cost of diagnostic equipment
    • 5.2.3 OPPORTUNITIES
      • 5.2.3.1 Introduction of disease-specific biomarkers and tests
    • TABLE 4 APPLICATION OF CANCER BIOMARKERS IN CLINICAL PRACTICE
      • 5.2.3.2 Growing significance of companion diagnostics
      • 5.2.3.3 Growth opportunities in emerging markets
    • TABLE 5 RECENT DEVELOPMENTS IN EMERGING MARKETS
      • 5.2.3.4 Improvements in immunoassay diagnostic technologies
      • 5.2.3.5 Trend of digitalization
    • 5.2.4 CHALLENGES
      • 5.2.4.1 Operational barriers
    • TABLE 6 IMPACT ANALYSIS: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
  • 5.3 PRICING ANALYSIS
    • 5.3.1 INDICATIVE AVERAGE SELLING PRICE OF REAGENTS & KITS (USD), BY REGION
    • 5.3.2 AVERAGE SELLING PRICE OF IMMUNOASSAY ANALYZERS (USD)
    • 5.3.3 AVERAGE SELLING PRICE OF LATERAL FLOW ANALYZERS (USD)
    • 5.3.4 AVERAGE SELLING PRICE OF MOLECULAR DIAGNOSTICS (USD)
    • 5.3.5 AVERAGE SELLING PRICE OF CLINICAL CHEMISTRY ANALYZERS (USD)
  • 5.4 VALUE CHAIN ANALYSIS
    • FIGURE 23 IN VITRO DIAGNOSTICS MARKET: VALUE CHAIN ANALYSIS
  • 5.5 SUPPLY CHAIN ANALYSIS
    • FIGURE 24 IN VITRO DIAGNOSTICS MARKET: SUPPLY CHAIN ANALYSIS
  • 5.6 PORTER'S FIVE FORCES ANALYSIS
    • TABLE 7 IN VITRO DIAGNOSTICS MARKET: PORTER'S FIVE FORCES ANALYSIS
    • 5.6.1 INTENSITY OF COMPETITIVE RIVALRY
    • 5.6.2 BARGAINING POWER OF SUPPLIERS
    • 5.6.3 BARGAINING POWER OF BUYERS
    • 5.6.4 THREAT OF NEW ENTRANTS
    • 5.6.5 THREAT OF SUBSTITUTES
  • 5.7 ECOSYSTEM ANALYSIS
    • FIGURE 25 IN VITRO DIAGNOSTICS MARKET: ECOSYSTEM MAP
    • 5.7.1 IN VITRO DIAGNOSTICS MARKET: ROLE IN ECOSYSTEM
  • 5.8 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
    • TABLE 8 LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
  • 5.9 REGULATORY ANALYSIS
    • 5.9.1 NORTH AMERICA
      • 5.9.1.1 US
    • TABLE 9 US: CLASSIFICATION OF IN VITRO DIAGNOSTIC DEVICES
    • FIGURE 26 US: REGULATORY PROCESS FOR IVD DEVICES
      • 5.9.1.2 Canada
    • FIGURE 27 CANADA: REGULATORY PROCESS FOR IVD DEVICES IN CANADA
    • 5.9.2 EUROPE
    • TABLE 10 EUROPE: CLASSIFICATION OF IVD DEVICES
    • FIGURE 28 EUROPE: IVDR TIMELINE
    • 5.9.3 ASIA PACIFIC
      • 5.9.3.1 Japan
    • FIGURE 29 REGULATORY PROCESS FOR IVD DEVICES IN JAPAN
    • TABLE 11 JAPAN: CLASSIFICATION OF IVD REAGENTS IN JAPAN
    • TABLE 12 JAPAN: TIME, COST, AND COMPLEXITY OF REGISTRATION PROCESS
      • 5.9.3.2 China
    • TABLE 13 CHINA: TIME, COST, AND COMPLEXITY OF REGISTRATION PROCESS
      • 5.9.3.3 India
    • FIGURE 30 INDIA: REGULATORY PROCESS FOR IVD DEVICES
      • 5.9.3.4 South Korea
    • TABLE 14 SOUTH KOREA: TIME, COST, AND COMPLEXITY OF REGISTRATION PROCESS
      • 5.9.3.5 Indonesia
    • TABLE 15 INDONESIA: REGISTRATION PROCESS FOR IVD DEVICES
    • 5.9.4 RUSSIA
    • TABLE 16 RUSSIA: CLASSIFICATION OF IVD DEVICES
    • 5.9.5 MIDDLE EAST & AFRICA
      • 5.9.5.1 Saudi Arabia
    • TABLE 17 SAUDI ARABIA: TIME, COST, AND COMPLEXITY OF REGISTRATION PROCESS
      • 5.9.5.2 Africa
    • 5.9.6 LATIN AMERICA
      • 5.9.6.1 Mexico
    • FIGURE 31 MEXICO: REGULATORY PROCESS FOR IVD DEVICES
    • TABLE 18 MEXICO: TIME, COST, AND COMPLEXITY OF REGISTRATION PROCESS
      • 5.9.6.2 Brazil
  • 5.10 PATENT ANALYSIS
  • 5.11 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS' BUSINESSES
    • 5.11.1 REVENUE SHIFT FOR IN VITRO DIAGNOSTICS MARKET
  • 5.12 KEY CONFERENCES & EVENTS
    • TABLE 19 IN VITRO DIAGNOSTICS MARKET: DETAILED LIST OF CONFERENCES & EVENTS (2024)
  • 5.13 TECHNOLOGY ANALYSIS
    • 5.13.1 IN VITRO DIAGNOSTICS MARKET: KEY TECHNOLOGIES
    • 5.13.2 IN VITRO DIAGNOSTICS MARKET: ADJACENT TECHNOLOGIES
  • 5.14 KEY STAKEHOLDERS AND BUYING CRITERIA
    • 5.14.1 KEY STAKEHOLDERS IN BUYING PROCESS
    • FIGURE 32 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS FOR IVD PRODUCTS
    • TABLE 20 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS OF IVD PRODUCTS (%)
    • 5.14.2 BUYING CRITERIA
    • FIGURE 33 KEY BUYING CRITERIA FOR IVD PRODUCTS
    • TABLE 21 KEY BUYING CRITERIA FOR IN VITRO DIAGNOSTIC PRODUCTS
  • 5.15 TRADE ANALYSIS
    • 5.15.1 TRADE ANALYSIS FOR IVD PRODUCTS
    • TABLE 22 IMPORT DATA FOR HS CODE 382200, BY COUNTRY, 2018-2022 (USD MILLION)
    • TABLE 23 EXPORT DATA FOR HS CODE 382200, BY COUNTRY, 2018-2022 (USD MILLION)

6 IN VITRO DIAGNOSTICS MARKET, BY PRODUCT & SERVICE

  • 6.1 INTRODUCTION
    • TABLE 24 IN VITRO DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2021-2029 (USD MILLION)
  • 6.2 REAGENTS & KITS
    • 6.2.1 INCREASING DEMAND FOR RAPID AND POINT-OF-CARE DIAGNOSTICS TO DRIVE MARKET
    • TABLE 25 IN VITRO DIAGNOSTICS MARKET FOR REAGENTS & KITS, BY REGION, 2021-2029 (USD MILLION)
    • TABLE 26 NORTH AMERICA: IN VITRO DIAGNOSTICS MARKET FOR REAGENTS & KITS, BY COUNTRY, 2021-2029 (USD MILLION)
    • TABLE 27 EUROPE: IN VITRO DIAGNOSTICS MARKET FOR REAGENTS & KITS, BY COUNTRY, 2021-2029 (USD MILLION)
    • TABLE 28 ASIA PACIFIC: IN VITRO DIAGNOSTICS MARKET FOR REAGENTS & KITS, BY COUNTRY, 2021-2029 (USD MILLION)
    • TABLE 29 LATIN AMERICA: IN VITRO DIAGNOSTICS FOR REAGENTS & KITS, BY COUNTRY, 2021-2029 (USD MILLION)
    • TABLE 30 GCC COUNTRIES: IN VITRO DIAGNOSTICS MARKET FOR REAGENTS & KITS, BY COUNTRY, 2021-2029 (USD MILLION)
  • 6.3 INSTRUMENTS
    • 6.3.1 RISING TREND OF AUTOMATION TO DRIVE MARKET
    • TABLE 31 KEY INSTRUMENTS AVAILABLE IN IVD MARKET
    • TABLE 32 IN VITRO DIAGNOSTICS MARKET FOR INSTRUMENTS, BY REGION, 2021-2029 (USD MILLION)
    • TABLE 33 NORTH AMERICA: IN VITRO DIAGNOSTICS MARKET FOR INSTRUMENTS, BY COUNTRY, 2021-2029 (USD MILLION)
    • TABLE 34 EUROPE: IN VITRO DIAGNOSTICS MARKET FOR INSTRUMENTS, BY COUNTRY, 2021-2029 (USD MILLION)
    • TABLE 35 ASIA PACIFIC: IN VITRO DIAGNOSTICS MARKET FOR INSTRUMENTS, BY COUNTRY, 2021-2029 (USD MILLION)
    • TABLE 36 LATIN AMERICA: IN VITRO DIAGNOSTICS MARKET FOR INSTRUMENTS, BY COUNTRY, 2021-2029 (USD MILLION)
    • TABLE 37 GCC COUNTRIES: IN VITRO DIAGNOSTICS MARKET FOR INSTRUMENTS, BY COUNTRY, 2021-2029 (USD MILLION)
  • 6.4 DATA MANAGEMENT SOFTWARE AND SERVICES
    • 6.4.1 ABILITY TO IMPROVE OPERATIONAL EFFICIENCY TO SUPPORT MARKET GROWTH
    • TABLE 38 KEY DATA MANAGEMENT SOFTWARE SOLUTIONS AVAILABLE IN IVD MARKET
    • TABLE 39 IN VITRO DIAGNOSTICS MARKET FOR DATA MANAGEMENT SOFTWARE AND SERVICES, BY REGION, 2021-2029 (USD MILLION)
    • TABLE 40 NORTH AMERICA: IN VITRO DIAGNOSTICS MARKET FOR DATA MANAGEMENT SOFTWARE AND SERVICES, BY COUNTRY, 2021-2029 (USD MILLION)
    • TABLE 41 EUROPE: IN VITRO DIAGNOSTICS MARKET FOR DATA MANAGEMENT SOFTWARE AND SERVICES, BY COUNTRY, 2021-2029 (USD MILLION)
    • TABLE 42 ASIA PACIFIC: IN VITRO DIAGNOSTICS MARKET FOR DATA MANAGEMENT SOFTWARE AND SERVICES, BY COUNTRY, 2021-2029 (USD MILLION)
    • TABLE 43 LATIN AMERICA: IN VITRO DIAGNOSTICS MARKET FOR DATA MANAGEMENT SOFTWARE AND SERVICES, BY COUNTRY, 2021-2029 (USD MILLION)
    • TABLE 44 GCC COUNTRIES: IN VITRO DIAGNOSTICS MARKET FOR DATA MANAGEMENT SOFTWARE AND SERVICES, BY COUNTRY, 2021-2029 (USD MILLION)

7 IN VITRO DIAGNOSTICS MARKET, BY TECHNOLOGY

  • 7.1 INTRODUCTION
    • TABLE 45 IN VITRO DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021-2029 (USD MILLION)
  • 7.2 IMMUNOASSAYS
    • TABLE 46 KEY IMMUNOASSAY ANALYZERS AVAILABLE IN IVD MARKET
    • TABLE 47 IN VITRO DIAGNOSTICS MARKET FOR IMMUNOASSAYS, BY TYPE, 2021-2029 (USD MILLION)
    • TABLE 48 IN VITRO DIAGNOSTICS MARKET FOR IMMUNOASSAYS, BY REGION, 2021-2029 (USD MILLION)
    • TABLE 49 NORTH AMERICA: IN VITRO DIAGNOSTICS MARKET FOR IMMUNOASSAYS, BY COUNTRY, 2021-2029 (USD MILLION)
    • TABLE 50 EUROPE: IN VITRO DIAGNOSTICS MARKET FOR IMMUNOASSAYS, BY COUNTRY, 2021-2029 ((USD MILLION)
    • TABLE 51 ASIA PACIFIC: IN VITRO DIAGNOSTICS MARKET FOR IMMUNOASSAYS, BY COUNTRY, 2021-2029 (USD MILLION)
    • TABLE 52 LATIN AMERICA: IN VITRO DIAGNOSTICS MARKET FOR IMMUNOASSAYS, BY COUNTRY, 2021-2029 (USD MILLION)
    • TABLE 53 GCC COUNTRIES: IN VITRO DIAGNOSTICS MARKET FOR IMMUNOASSAYS, BY COUNTRY, 2021-2029 (USD MILLION)
    • 7.2.1 ENZYME-LINKED IMMUNOSORBENT ASSAYS (ELISA)
      • 7.2.1.1 Utilization in viral disease diagnostics and drug discovery to boost demand
    • TABLE 54 KEY ELISA ANALYZERS AVAILABLE IN IVD MARKET
    • TABLE 55 IN VITRO DIAGNOSTICS MARKET FOR ELISA, BY REGION, 2021-2029 (USD MILLION)
    • TABLE 56 NORTH AMERICA: IN VITRO DIAGNOSTICS MARKET FOR ELISA, BY COUNTRY, 2021-2029 (USD MILLION)
    • TABLE 57 EUROPE: IN VITRO DIAGNOSTICS MARKET FOR ELISA, BY COUNTRY, 2021-2029 (USD MILLION)
    • TABLE 58 ASIA PACIFIC: IN VITRO DIAGNOSTICS MARKET FOR ELISA, BY COUNTRY, 2021-2029 (USD MILLION)
    • TABLE 59 LATIN AMERICA: IN VITRO DIAGNOSTICS MARKET FOR ELISA, BY COUNTRY, 2021-2029 (USD MILLION)
    • TABLE 60 GCC COUNTRIES: IN VITRO DIAGNOSTICS MARKET FOR ELISA, BY COUNTRY, 2021-2029 (USD MILLION)
    • 7.2.2 CHEMILUMINESCENCE IMMUNOASSAYS
      • 7.2.2.1 High sensitivity and wide detection range to fuel market
    • TABLE 61 KEY CHEMILUMINESCENCE IMMUNOASSAY SYSTEMS AVAILABLE IN IVD MARKET
    • TABLE 62 IN VITRO DIAGNOSTICS MARKET FOR CHEMILUMINESCENCE IMMUNOASSAYS, BY REGION, 2021-2029 (USD MILLION)
    • TABLE 63 NORTH AMERICA: IN VITRO DIAGNOSTICS MARKET FOR CHEMILUMINESCENCE IMMUNOASSAYS, BY COUNTRY, 2021-2029 (USD MILLION)
    • TABLE 64 EUROPE: IN VITRO DIAGNOSTICS MARKET FOR CHEMILUMINESCENCE IMMUNOASSAYS, BY COUNTRY, 2021-2029 (USD MILLION)
    • TABLE 65 ASIA PACIFIC: IN VITRO DIAGNOSTICS MARKET FOR CHEMILUMINESCENCE IMMUNOASSAYS, BY COUNTRY, 2021-2029 (USD MILLION)
    • TABLE 66 LATIN AMERICA: IN VITRO DIAGNOSTICS MARKET FOR CHEMILUMINESCENCE IMMUNOASSAYS, BY COUNTRY, 2021-2029 (USD MILLION)
    • TABLE 67 GCC COUNTRIES: IN VITRO DIAGNOSTICS MARKET FOR CHEMILUMINESCENCE IMMUNOASSAYS, BY COUNTRY, 2021-2029 (USD MILLION)
    • 7.2.3 IMMUNOFLUORESCENCE ASSAYS
      • 7.2.3.1 HIV antibody diagnosis in medical research to support market growth
    • TABLE 68 IN VITRO DIAGNOSTICS MARKET FOR IMMUNOFLUORESCENCE ASSAYS, BY REGION, 2021-2029 (USD MILLION)
    • TABLE 69 NORTH AMERICA: IN VITRO DIAGNOSTICS MARKET FOR IMMUNOFLUORESCENCE ASSAYS, BY COUNTRY, 2021-2029 (USD MILLION)
    • TABLE 70 EUROPE: IN VITRO DIAGNOSTICS MARKET FOR IMMUNOFLUORESCENCE ASSAYS, BY COUNTRY, 2021-2029 (USD MILLION)
    • TABLE 71 ASIA PACIFIC: IN VITRO DIAGNOSTICS MARKET FOR IMMUNOFLUORESCENCE ASSAYS, BY COUNTRY, 2021-2029 (USD MILLION)
    • TABLE 72 LATIN AMERICA: IN VITRO DIAGNOSTICS MARKET FOR IMMUNOFLUORESCENCE ASSAYS, BY COUNTRY, 2021-2029 (USD MILLION)
    • TABLE 73 GCC COUNTRIES: IN VITRO DIAGNOSTICS MARKET FOR IMMUNOFLUORESCENCE ASSAYS, BY COUNTRY, 2021-2029 (USD MILLION)
    • 7.2.4 RAPID TESTS
      • 7.2.4.1 Rising usage in emergency care to drive market
    • TABLE 74 KEY RAPID TESTS AVAILABLE IN IVD MARKET
    • TABLE 75 IN VITRO DIAGNOSTICS MARKET FOR RAPID TESTS, BY REGION, 2021-2029 (USD MILLION)
    • TABLE 76 NORTH AMERICA: IN VITRO DIAGNOSTICS MARKET FOR RAPID TESTS, BY COUNTRY, 2021-2029 (USD MILLION)
    • TABLE 77 EUROPE: IN VITRO DIAGNOSTICS MARKET FOR RAPID TESTS, BY COUNTRY, 2021-2029 (USD MILLION)
    • TABLE 78 ASIA PACIFIC: IN VITRO DIAGNOSTICS MARKET FOR RAPID TESTS, BY COUNTRY, 2021-2029 (USD MILLION)
    • TABLE 79 LATIN AMERICA: IN VITRO DIAGNOSTICS MARKET FOR RAPID TESTS, BY COUNTRY, 2021-2029 (USD MILLION)
    • TABLE 80 GCC COUNTRIES: IN VITRO DIAGNOSTICS MARKET FOR RAPID TESTS, BY COUNTRY, 2021-2029 (USD MILLION)
    • 7.2.5 ENZYME-LINKED IMMUNOSPOT ASSAYS (ELISPOT)
      • 7.2.5.1 Rapid analysis of samples and high functionality to boost demand
    • TABLE 81 IN VITRO DIAGNOSTICS MARKET FOR ELISPOT, BY REGION, 2021-2029 (USD MILLION)
    • TABLE 82 NORTH AMERICA: IN VITRO DIAGNOSTICS MARKET FOR ELISPOT, BY COUNTRY, 2021-2029 (USD MILLION)
    • TABLE 83 EUROPE: IN VITRO DIAGNOSTICS MARKET FOR ELISPOT, BY COUNTRY, 2021-2029 (USD MILLION)
    • TABLE 84 ASIA PACIFIC: IN VITRO DIAGNOSTICS MARKET FOR ELISPOT, BY COUNTRY, 2021-2029 (USD MILLION)
    • TABLE 85 LATIN AMERICA: IN VITRO DIAGNOSTICS MARKET FOR ELISPOT, BY COUNTRY, 2021-2029 (USD MILLION)
    • TABLE 86 GCC COUNTRIES: IN VITRO DIAGNOSTICS MARKET ELISPOT, BY COUNTRY, 2021-2029 (USD MILLION)
    • 7.2.6 WESTERN BLOTTING
      • 7.2.6.1 Gold standard for result validation to boost demand
    • TABLE 87 KEY WESTERN BLOTTING SYSTEMS AVAILABLE IN IVD MARKET
    • TABLE 88 IN VITRO DIAGNOSTICS MARKET FOR WESTERN BLOTTING, BY REGION, 2021-2029 (USD MILLION)
    • TABLE 89 NORTH AMERICA: IN VITRO DIAGNOSTICS MARKET FOR WESTERN BLOTTING, BY COUNTRY, 2021-2029 (USD MILLION)
    • TABLE 90 EUROPE: IN VITRO DIAGNOSTICS MARKET FOR WESTERN BLOTTING, BY COUNTRY, 2021-2029 (USD MILLION)
    • TABLE 91 ASIA PACIFIC: IN VITRO DIAGNOSTICS MARKET FOR WESTERN BLOTTING, BY COUNTRY, 2021-2029 (USD MILLION)
    • TABLE 92 LATIN AMERICA: IN VITRO DIAGNOSTICS MARKET FOR WESTERN BLOTTING, BY COUNTRY, 2021-2029 (USD MILLION)
    • TABLE 93 GCC COUNTRIES: IN VITRO DIAGNOSTICS MARKET FOR WESTERN BLOTTING, BY COUNTRY, 2021-2029 (USD MILLION)
    • 7.2.7 OTHER IMMUNOASSAY TECHNOLOGIES
    • TABLE 94 IN VITRO DIAGNOSTICS MARKET FOR OTHER IMMUNOASSAY TECHNOLOGIES, BY REGION, 2021-2029 (USD MILLION)
    • TABLE 95 NORTH AMERICA: IN VITRO DIAGNOSTICS MARKET FOR OTHER IMMUNOASSAY TECHNOLOGIES, BY COUNTRY, 2021-2029 (USD MILLION)
    • TABLE 96 EUROPE: IN VITRO DIAGNOSTICS MARKET FOR OTHER IMMUNOASSAY TECHNOLOGIES, BY COUNTRY, 2021-2029 (USD MILLION)
    • TABLE 97 ASIA PACIFIC: IN VITRO DIAGNOSTICS MARKET FOR OTHER IMMUNOASSAY TECHNOLOGIES, BY COUNTRY, 2021-2029 (USD MILLION)
    • TABLE 98 LATIN AMERICA: IN VITRO DIAGNOSTICS MARKET FOR OTHER IMMUNOASSAY TECHNOLOGIES, BY COUNTRY, 2021-2029 (USD MILLION)
    • TABLE 99 GCC COUNTRIES: IN VITRO DIAGNOSTICS MARKET FOR OTHER IMMUNOASSAY TECHNOLOGIES, BY COUNTRY, 2021-2029 (USD MILLION)
  • 7.3 CLINICAL CHEMISTRY
    • TABLE 100 CLINICAL CHEMISTRY ANALYZERS FOR HIGH AND MID-VOLUME LABORATORIES
    • TABLE 101 CLINICAL CHEMISTRY ANALYZERS FOR LOW-VOLUME LABORATORIES
    • TABLE 102 IN VITRO DIAGNOSTICS MARKET FOR CLINICAL CHEMISTRY, BY TYPE, 2021-2029 (USD MILLION)
    • TABLE 103 IN VITRO DIAGNOSTICS MARKET FOR CLINICAL CHEMISTRY, BY REGION, 2021-2029 (USD MILLION)
    • TABLE 104 NORTH AMERICA: IN VITRO DIAGNOSTICS MARKET FOR CLINICAL CHEMISTRY, BY COUNTRY, 2021-2029 (USD MILLION)
    • TABLE 105 EUROPE: IN VITRO DIAGNOSTICS MARKET FOR CLINICAL CHEMISTRY, BY COUNTRY, 2021-2029 (USD MILLION)
    • TABLE 106 ASIA PACIFIC: IN VITRO DIAGNOSTICS MARKET FOR CLINICAL CHEMISTRY, BY COUNTRY, 2021-2029 (USD MILLION)
    • TABLE 107 LATIN AMERICA: IN VITRO DIAGNOSTICS MARKET FOR CLINICAL CHEMISTRY, BY COUNTRY, 2021-2029 (USD MILLION)
    • TABLE 108 GCC COUNTRIES: IN VITRO DIAGNOSTICS MARKET FOR CLINICAL CHEMISTRY, BY COUNTRY, 2021-2029 (USD MILLION)
    • 7.3.1 BASIC METABOLIC PANELS
      • 7.3.1.1 Rising prevalence of diabetes to boost demand
    • TABLE 109 IN VITRO DIAGNOSTICS MARKET FOR BASIC METABOLIC PANELS, BY REGION, 2021-2029 (USD MILLION)
    • TABLE 110 NORTH AMERICA: IN VITRO DIAGNOSTICS MARKET FOR BASIC METABOLIC PANELS, BY COUNTRY, 2021-2029 (USD MILLION)
    • TABLE 111 EUROPE: IN VITRO DIAGNOSTICS MARKET FOR BASIC METABOLIC PANELS, BY COUNTRY, 2021-2029 (USD MILLION)
    • TABLE 112 ASIA PACIFIC: IN VITRO DIAGNOSTICS MARKET FOR BASIC METABOLIC PANELS, BY COUNTRY, 2021-2029 (USD MILLION)
    • TABLE 113 LATIN AMERICA: IN VITRO DIAGNOSTICS MARKET FOR BASIC METABOLIC PANELS, BY COUNTRY, 2021-2029 (USD MILLION)
    • TABLE 114 GCC COUNTRIES: IN VITRO DIAGNOSTICS MARKET FOR BASIC METABOLIC PANELS, BY COUNTRY, 2021-2029 (USD MILLION)
    • 7.3.2 LIVER PANELS
      • 7.3.2.1 Rising prevalence of cirrhosis and viral hepatitis to fuel market
    • TABLE 115 IN VITRO DIAGNOSTICS MARKET FOR LIVER PANELS, BY REGION, 2021-2029 (USD MILLION)
    • TABLE 116 NORTH AMERICA: IN VITRO DIAGNOSTICS MARKET FOR LIVER PANELS, BY COUNTRY, 2021-2029 (USD MILLION)
    • TABLE 117 EUROPE: IN VITRO DIAGNOSTICS MARKET FOR LIVER PANELS, BY COUNTRY, 2021-2029 (USD MILLION)
    • TABLE 118 ASIA PACIFIC: IN VITRO DIAGNOSTICS MARKET FOR LIVER PANELS, BY COUNTRY, 2021-2029 (USD MILLION)
    • TABLE 119 LATIN AMERICA: IN VITRO DIAGNOSTICS MARKET FOR LIVER PANELS, BY COUNTRY, 2021-2029 (USD MILLION)
    • TABLE 120 GCC COUNTRIES: IN VITRO DIAGNOSTICS MARKET FOR LIVER PANELS, BY COUNTRY, 2021-2029 (USD MILLION)
    • 7.3.3 RENAL PROFILES
      • 7.3.3.1 Ability to monitor cytokines & chemokines in urine to propel market
    • TABLE 121 IN VITRO DIAGNOSTICS MARKET FOR RENAL PROFILES, BY REGION, 2021-2029 (USD MILLION)
    • TABLE 122 NORTH AMERICA: IN VITRO DIAGNOSTICS MARKET FOR RENAL PROFILES, BY COUNTRY, 2021-2029 (USD MILLION)
    • TABLE 123 EUROPE: IN VITRO DIAGNOSTICS MARKET FOR RENAL PROFILES, BY COUNTRY, 2021-2029 (USD MILLION)
    • TABLE 124 ASIA PACIFIC: IN VITRO DIAGNOSTICS MARKET FOR RENAL PROFILES, BY COUNTRY, 2021-2029 (USD MILLION)
    • TABLE 125 LATIN AMERICA: IN VITRO DIAGNOSTICS MARKET FOR RENAL PROFILES, BY COUNTRY, 2021-2029 (USD MILLION)
    • TABLE 126 GCC COUNTRIES: IN VITRO DIAGNOSTICS MARKET FOR RENAL PROFILES, BY COUNTRY, 2021-2029 (USD MILLION)
    • 7.3.4 LIPID PROFILES
      • 7.3.4.1 Determination of total cholesterol and risk status for CVD to boost demand
    • TABLE 127 IN VITRO DIAGNOSTICS MARKET FOR LIPID PROFILES, BY REGION, 2021-2029 (USD MILLION)
    • TABLE 128 NORTH AMERICA: IN VITRO DIAGNOSTICS MARKET FOR LIPID PROFILES, BY COUNTRY, 2021-2029 (USD MILLION)
    • TABLE 129 EUROPE: IN VITRO DIAGNOSTICS MARKET FOR LIPID PROFILES, BY COUNTRY, 2021-2029 (USD MILLION)
    • TABLE 130 ASIA PACIFIC: IN VITRO DIAGNOSTICS MARKET FOR LIPID PROFILES, BY COUNTRY, 2021-2029 (USD MILLION)
    • TABLE 131 LATIN AMERICA: IN VITRO DIAGNOSTICS MARKET FOR LIPID PROFILES, BY COUNTRY, 2021-2029 (USD MILLION)
    • TABLE 132 GCC COUNTRIES: IN VITRO DIAGNOSTICS MARKET FOR LIPID PROFILES, BY COUNTRY, 2021-2029 (USD MILLION)
    • 7.3.5 THYROID FUNCTION PANELS
      • 7.3.5.1 High incidence of thyroid-related disorders to support market growth
    • TABLE 133 IN VITRO DIAGNOSTICS MARKET FOR THYROID FUNCTION PROFILES, BY REGION, 2021-2029 (USD MILLION)
    • TABLE 134 NORTH AMERICA: IN VITRO DIAGNOSTICS MARKET FOR THYROID FUNCTION PROFILES, BY COUNTRY, 2021-2029 (USD MILLION)
    • TABLE 135 EUROPE: IN VITRO DIAGNOSTICS MARKET FOR THYROID FUNCTION PROFILES, BY COUNTRY, 2021-2029 (USD MILLION)
    • TABLE 136 ASIA PACIFIC: IN VITRO DIAGNOSTICS MARKET FOR THYROID FUNCTION PROFILES, BY COUNTRY, 2021-2029 (USD MILLION)
    • TABLE 137 LATIN AMERICA: IN VITRO DIAGNOSTICS MARKET FOR THYROID FUNCTION PROFILES, BY COUNTRY, 2021-2029 (USD MILLION)
    • TABLE 138 GCC COUNTRIES: IN VITRO DIAGNOSTICS MARKET FOR THYROID FUNCTION PROFILES, BY COUNTRY, 2021-2029 (USD MILLION)
    • 7.3.6 ELECTROLYTE PANELS
      • 7.3.6.1 Ability to diagnose hypertension and heart failure to support uptake
    • TABLE 139 IN VITRO DIAGNOSTICS MARKET FOR ELECTROLYTE PANELS, BY REGION, 2021-2029 (USD MILLION)
    • TABLE 140 NORTH AMERICA: IN VITRO DIAGNOSTICS MARKET FOR ELECTROLYTE PANELS, BY COUNTRY, 2021-2029 (USD MILLION)
    • TABLE 141 EUROPE: IN VITRO DIAGNOSTICS MARKET FOR ELECTROLYTE PANELS, BY COUNTRY, 2021-2029 (USD MILLION)
    • TABLE 142 ASIA PACIFIC: IN VITRO DIAGNOSTICS MARKET FOR ELECTROLYTE PANELS, BY COUNTRY, 2021-2029 (USD MILLION)
    • TABLE 143 LATIN AMERICA: IN VITRO DIAGNOSTICS MARKET FOR ELECTROLYTE PANELS, BY COUNTRY, 2021-2029 (USD MILLION)
    • TABLE 144 GCC COUNTRIES: IN VITRO DIAGNOSTICS MARKET FOR ELECTROLYTE PANELS, BY COUNTRY, 2021-2029 (USD MILLION)
    • 7.3.7 SPECIALTY CHEMICAL TESTS
      • 7.3.7.1 Inclusion of immunosuppressant drug monitoring and drugs of abuse to support market growth
    • TABLE 145 IN VITRO DIAGNOSTICS MARKET FOR SPECIALTY CHEMICAL TESTS, BY REGION, 2021-2029 (USD MILLION)
    • TABLE 146 NORTH AMERICA: IN VITRO DIAGNOSTICS MARKET FOR SPECIALTY CHEMICAL TESTS, BY COUNTRY, 2021-2029 (USD MILLION)
    • TABLE 147 EUROPE: IN VITRO DIAGNOSTICS MARKET FOR SPECIALTY CHEMICAL TESTS, BY COUNTRY, 2021-2029 (USD MILLION)
    • TABLE 148 ASIA PACIFIC: IN VITRO DIAGNOSTICS MARKET FOR SPECIALTY CHEMICAL TESTS, BY COUNTRY, 2021-2029 (USD MILLION)
    • TABLE 149 LATIN AMERICA: IN VITRO DIAGNOSTICS MARKET FOR SPECIALTY CHEMICAL TESTS, BY COUNTRY, 2021-2029 (USD MILLION)
    • TABLE 150 GCC COUNTRIES: IN VITRO DIAGNOSTICS MARKET FOR SPECIALTY CHEMICAL TESTS, BY COUNTRY, 2021-2029 (USD MILLION)
  • 7.4 MOLECULAR DIAGNOSTICS
    • TABLE 151 KEY AUTOMATED MOLECULAR DIAGNOSTIC PLATFORMS AVAILABLE IN IVD MARKET
    • TABLE 152 IN VITRO DIAGNOSTICS MARKET FOR MOLECULAR DIAGNOSTICS, BY TYPE, 2021-2029 (USD MILLION)
    • TABLE 153 IN VITRO DIAGNOSTICS MARKET FOR MOLECULAR DIAGNOSTICS, BY REGION, 2021-2029 (USD MILLION)
    • TABLE 154 NORTH AMERICA: IN VITRO DIAGNOSTICS MARKET FOR MOLECULAR DIAGNOSTICS, BY COUNTRY, 2021-2029 (USD MILLION)
    • TABLE 155 EUROPE: IN VITRO DIAGNOSTICS MARKET FOR MOLECULAR DIAGNOSTICS, BY COUNTRY, 2021-2029 (USD MILLION)
    • TABLE 156 ASIA PACIFIC: IN VITRO DIAGNOSTICS MARKET FOR MOLECULAR DIAGNOSTICS, BY COUNTRY, 2021-2029 (USD MILLION)
    • TABLE 157 LATIN AMERICA: IN VITRO DIAGNOSTICS MARKET FOR MOLECULAR DIAGNOSTICS, BY COUNTRY, 2021-2029 (USD MILLION)
    • TABLE 158 GCC COUNTRIES: IN VITRO DIAGNOSTICS MARKET FOR MOLECULAR DIAGNOSTICS, BY COUNTRY, 2021-2029 (USD MILLION)
    • 7.4.1 POLYMERASE CHAIN REACTION (PCR)
      • 7.4.1.1 High specificity of RT-PCR tests to drive market
    • TABLE 159 KEY PCR INSTRUMENTS AVAILABLE IN IVD MARKET
    • TABLE 160 IN VITRO DIAGNOSTICS MARKET FOR PCR, BY REGION, 2021-2029 (USD MILLION)
    • TABLE 161 NORTH AMERICA: IN VITRO DIAGNOSTICS MARKET FOR PCR, BY COUNTRY, 2021-2029 (USD MILLION)
    • TABLE 162 EUROPE: IN VITRO DIAGNOSTICS MARKET FOR PCR, BY COUNTRY, 2021-2029 (USD MILLION)
    • TABLE 163 ASIA PACIFIC: IN VITRO DIAGNOSTICS MARKET FOR PCR, BY COUNTRY, 2021-2029 (USD MILLION)
    • TABLE 164 LATIN AMERICA: IN VITRO DIAGNOSTICS MARKET FOR PCR, BY COUNTRY, 2021-2029 (USD MILLION)
    • TABLE 165 GCC COUNTRIES: IN VITRO DIAGNOSTICS MARKET FOR PCR, BY COUNTRY, 2021-2029 (USD MILLION)
    • 7.4.2 ISOTHERMAL NUCLEIC ACID AMPLIFICATION TECHNOLOGY (INAAT)
      • 7.4.2.1 Cost benefits to drive market
    • TABLE 166 IN VITRO DIAGNOSTICS MARKET FOR INAAT, BY REGION, 2021-2029 (USD MILLION)
    • TABLE 167 NORTH AMERICA: IN VITRO DIAGNOSTICS MARKET FOR INAAT, BY COUNTRY, 2021-2029 (USD MILLION)
    • TABLE 168 EUROPE: IN VITRO DIAGNOSTICS MARKET FOR INAAT, BY COUNTRY, 2021-2029 (USD MILLION)
    • TABLE 169 ASIA PACIFIC: IN VITRO DIAGNOSTICS MARKET FOR INAAT, BY COUNTRY, 2021-2029 (USD MILLION)
    • TABLE 170 LATIN AMERICA: IN VITRO DIAGNOSTICS MARKET FOR INAAT, BY COUNTRY, 2021-2029 (USD MILLION)
    • TABLE 171 GCC COUNTRIES: IN VITRO DIAGNOSTICS MARKET FOR INAAT, BY COUNTRY, 2021-2029 (USD MILLION)
    • 7.4.3 DNA SEQUENCING & NEXT-GENERATION SEQUENCING (NGS)
      • 7.4.3.1 Declining costs of NGS-based tests to boost demand
    • TABLE 172 IN VITRO DIAGNOSTICS MARKET FOR DNA SEQUENCING & NGS, BY REGION, 2021-2029 (USD MILLION)
    • TABLE 173 NORTH AMERICA: IN VITRO DIAGNOSTICS MARKET FOR DNA SEQUENCING & NGS, BY COUNTRY, 2021-2029 (USD MILLION)
    • TABLE 174 EUROPE: IN VITRO DIAGNOSTICS MARKET FOR DNA SEQUENCING & NGS, BY COUNTRY, 2021-2029 (USD MILLION)
    • TABLE 175 ASIA PACIFIC: IN VITRO DIAGNOSTICS MARKET FOR DNA SEQUENCING & NGS, BY COUNTRY, 2021-2029 (USD MILLION)
    • TABLE 176 LATIN AMERICA: IN VITRO DIAGNOSTICS MARKET FOR DNA SEQUENCING & NGS, 2021-2029 (USD MILLION)
    • TABLE 177 GCC COUNTRIES: IN VITRO DIAGNOSTICS MARKET FOR DNA SEQUENCING & NGS, BY COUNTRY, 2021-2029 (USD MILLION)
    • 7.4.4 IN SITU HYBRIDIZATION (ISH)
      • 7.4.4.1 Rising prevalence of cancer and genetic disorders to drive market
    • TABLE 178 IN VITRO DIAGNOSTICS MARKET FOR ISH, BY REGION, 2021-2029 (USD MILLION)
    • TABLE 179 NORTH AMERICA: IN VITRO DIAGNOSTICS MARKET FOR ISH, BY COUNTRY, 2021-2029 (USD MILLION)
    • TABLE 180 EUROPE: IN VITRO DIAGNOSTICS MARKET FOR ISH, BY COUNTRY, 2021-2029 (USD MILLION)
    • TABLE 181 ASIA PACIFIC: IN VITRO DIAGNOSTICS MARKET FOR ISH, BY COUNTRY, 2021-2029 (USD MILLION)
    • TABLE 182 LATIN AMERICA: IN VITRO DIAGNOSTICS MARKET FOR ISH, BY COUNTRY, 2021-2029 (USD MILLION)
    • TABLE 183 GCC COUNTRIES: IN VITRO DIAGNOSTICS MARKET FOR ISH, BY COUNTRY, 2021-2029 (USD MILLION)
    • 7.4.5 DNA MICROARRAYS
      • 7.4.5.1 High resolution and throughput capabilities to support market growth
    • TABLE 184 IN VITRO DIAGNOSTICS MARKET FOR DNA MICROARRAYS, BY REGION, 2021-2029 (USD MILLION)
    • TABLE 185 NORTH AMERICA: IN VITRO DIAGNOSTICS MARKET FOR DNA MICROARRAYS, BY COUNTRY, 2021-2029 (USD MILLION)
    • TABLE 186 EUROPE: IN VITRO DIAGNOSTICS MARKET FOR DNA MICROARRAYS, BY COUNTRY, 2021-2029 (USD MILLION)
    • TABLE 187 ASIA PACIFIC: IN VITRO DIAGNOSTICS MARKET FOR DNA MICROARRAYS, BY COUNTRY, 2021-2029 (USD MILLION)
    • TABLE 188 LATIN AMERICA: IN VITRO DIAGNOSTICS MARKET FOR DNA MICROARRAYS, BY COUNTRY, 2021-2029 (USD MILLION)
    • TABLE 189 GCC COUNTRIES: IN VITRO DIAGNOSTICS MARKET FOR DNA MICROARRAYS, BY COUNTRY, 2021-2029 (USD MILLION)
    • 7.4.6 OTHER MOLECULAR DIAGNOSTIC TECHNOLOGIES
  • Other molecular diagnostic technologies include electrophoresis and flow cytometry.
    • TABLE 190 IN VITRO DIAGNOSTICS MARKET FOR OTHER MOLECULAR DIAGNOSTIC TECHNOLOGIES, BY REGION, 2021-2029 (USD MILLION)
    • TABLE 191 NORTH AMERICA: IN VITRO DIAGNOSTICS MARKET FOR OTHER MOLECULAR DIAGNOSTIC TECHNOLOGIES, BY COUNTRY, 2021-2029 (USD MILLION)
    • TABLE 192 EUROPE: IN VITRO DIAGNOSTICS MARKET FOR OTHER MOLECULAR DIAGNOSTIC TECHNOLOGIES, BY COUNTRY, 2021-2029 (USD MILLION)
    • TABLE 193 ASIA PACIFIC: IN VITRO DIAGNOSTICS MARKET FOR OTHER MOLECULAR DIAGNOSTIC TECHNOLOGIES, BY COUNTRY, 2021-2029 (USD MILLION)
    • TABLE 194 LATIN AMERICA: IN VITRO DIAGNOSTICS MARKET FOR OTHER MOLECULAR DIAGNOSTIC TECHNOLOGIES, BY COUNTRY, 2021-2029 (USD MILLION)
    • TABLE 195 GCC COUNTRIES: IN VITRO DIAGNOSTICS MARKET FOR OTHER MOLECULAR DIAGNOSTIC TECHNOLOGIES, BY COUNTRY, 2021-2029 (USD MILLION)
  • 7.5 HEMATOLOGY
    • 7.5.1 GROWING FOCUS ON STEM CELL RESEARCH TO BOOST DEMAND
    • TABLE 196 IN VITRO DIAGNOSTICS MARKET FOR HEMATOLOGY, BY REGION, 2021-2029 (USD MILLION)
    • TABLE 197 NORTH AMERICA: IN VITRO DIAGNOSTICS MARKET FOR HEMATOLOGY, BY COUNTRY, 2021-2029 (USD MILLION)
    • TABLE 198 EUROPE: IN VITRO DIAGNOSTICS MARKET FOR HEMATOLOGY, BY COUNTRY, 2021-2029 (USD MILLION)
    • TABLE 199 ASIA PACIFIC: IN VITRO DIAGNOSTICS MARKET FOR HEMATOLOGY, BY COUNTRY, 2021-2029 (USD MILLION)
    • TABLE 200 LATIN AMERICA: IN VITRO DIAGNOSTICS MARKET FOR HEMATOLOGY, BY COUNTRY, 2021-2029 (USD MILLION)
    • TABLE 201 GCC COUNTRIES: IN VITRO DIAGNOSTICS MARKET FOR HEMATOLOGY, BY COUNTRY, 2021-2029 (USD MILLION)
  • 7.6 MICROBIOLOGY
    • 7.6.1 RISING PREVALENCE OF MICROBIAL INFECTIONS TO FUEL MARKET
    • TABLE 202 IN VITRO DIAGNOSTICS MARKET FOR MICROBIOLOGY, BY REGION, 2021-2029 (USD MILLION)
    • TABLE 203 NORTH AMERICA: IN VITRO DIAGNOSTICS MARKET FOR MICROBIOLOGY, BY COUNTRY, 2021-2029 (USD MILLION)
    • TABLE 204 EUROPE: IN VITRO DIAGNOSTICS MARKET FOR MICROBIOLOGY, BY COUNTRY, 2021-2029 (USD MILLION)
    • TABLE 205 ASIA PACIFIC: IN VITRO DIAGNOSTICS MARKET FOR MICROBIOLOGY, BY COUNTRY, 2021-2029 (USD MILLION)
    • TABLE 206 LATIN AMERICA: IN VITRO DIAGNOSTICS MARKET FOR MICROBIOLOGY, BY COUNTRY, 2021-2029 (USD MILLION)
    • TABLE 207 GCC COUNTRIES: IN VITRO DIAGNOSTICS MARKET FOR MICROBIOLOGY, BY COUNTRY, 2021-2029 (USD MILLION)
  • 7.7 COAGULATION & HEMOSTASIS
    • 7.7.1 GROWING USE OF ANTICOAGULATION THERAPY IN SURGICAL PROCEDURES TO DRIVE MARKET
    • TABLE 208 IN VITRO DIAGNOSTICS MARKET FOR COAGULATION & HEMOSTASIS, BY REGION, 2021-2029 (USD MILLION)
    • TABLE 209 NORTH AMERICA: IN VITRO DIAGNOSTICS MARKET FOR COAGULATION & HEMOSTASIS, BY COUNTRY, 2021-2029 (USD MILLION)
    • TABLE 210 EUROPE: IN VITRO DIAGNOSTICS MARKET FOR COAGULATION & HEMOSTASIS, BY COUNTRY, 2021-2029 (USD MILLION)
    • TABLE 211 ASIA PACIFIC: IN VITRO DIAGNOSTICS MARKET FOR COAGULATION & HEMOSTASIS, BY COUNTRY, 2021-2029 (USD MILLION)
    • TABLE 212 LATIN AMERICA: IN VITRO DIAGNOSTICS MARKET FOR COAGULATION & HEMOSTASIS, BY COUNTRY, 2021-2029 (USD MILLION)
    • TABLE 213 GCC COUNTRIES: IN VITRO DIAGNOSTICS MARKET FOR COAGULATION & HEMOSTASIS, BY COUNTRY, 2021-2029 (USD MILLION)
  • 7.8 URINALYSIS
    • 7.8.1 RISING INCIDENCE OF UTIS TO SUPPORT MARKET GROWTH
    • TABLE 214 IN VITRO DIAGNOSTICS MARKET FOR URINALYSIS, BY REGION, 2021-2029 (USD MILLION)
    • TABLE 215 NORTH AMERICA: IN VITRO DIAGNOSTICS MARKET FOR URINALYSIS, BY COUNTRY, 2021-2029 (USD MILLION)
    • TABLE 216 EUROPE: IN VITRO DIAGNOSTICS MARKET FOR URINALYSIS, BY COUNTRY, 2021-2029 (USD MILLION)
    • TABLE 217 ASIA PACIFIC: IN VITRO DIAGNOSTICS MARKET FOR URINALYSIS, BY COUNTRY, 2021-2029 (USD MILLION)
    • TABLE 218 LATIN AMERICA: IN VITRO DIAGNOSTICS MARKET FOR URINALYSIS, BY COUNTRY, 2021-2029 (USD MILLION)
    • TABLE 219 GCC COUNTRIES: IN VITRO DIAGNOSTICS MARKET FOR URINALYSIS, BY COUNTRY, 2021-2029 (USD MILLION)
  • 7.9 CHROMATOGRAPHY & MASS SPECTROMETRY
    • 7.9.1 METHODOLOGICAL IMPROVEMENTS AND TECHNOLOGICAL INNOVATIONS TO FUEL MARKET
    • TABLE 220 IN VITRO DIAGNOSTICS MARKET FOR CHROMATOGRAPHY & MASS SPECTROMETRY, BY REGION, 2021-2029 (USD MILLION)
    • TABLE 221 NORTH AMERICA: IN VITRO DIAGNOSTICS MARKET FOR CHROMATOGRAPHY & MASS SPECTROMETRY, BY COUNTRY, 2021-2029 (USD MILLION)
    • TABLE 222 EUROPE: IN VITRO DIAGNOSTICS MARKET FOR CHROMATOGRAPHY & MASS SPECTROMETRY, BY COUNTRY, 2021-2029 (USD MILLION)
    • TABLE 223 ASIA PACIFIC: IN VITRO DIAGNOSTICS MARKET FOR CHROMATOGRAPHY & MASS SPECTROMETRY, BY COUNTRY, 2021-2029 (USD MILLION)
    • TABLE 224 LATIN AMERICA: IN VITRO DIAGNOSTICS MARKET FOR CHROMATOGRAPHY & MASS SPECTROMETRY, BY COUNTRY, 2021-2029 (USD MILLION)
    • TABLE 225 GCC COUNTRIES: IN VITRO DIAGNOSTICS MARKET FOR CHROMATOGRAPHY & MASS SPECTROMETRY, BY COUNTRY, 2021-2029 (USD MILLION)

8 IN VITRO DIAGNOSTICS MARKET, BY SPECIMEN

  • 8.1 INTRODUCTION
    • TABLE 226 IN VITRO DIAGNOSTICS MARKET, BY SPECIMEN, 2021-2029 (USD MILLION)
  • 8.2 BLOOD, SERUM, AND PLASMA
    • 8.2.1 HIGH RELIABILITY FOR CHRONIC DISEASE DIAGNOSIS TO PROPEL MARKET
    • TABLE 227 IN VITRO DIAGNOSTICS MARKET FOR BLOOD, SERUM, AND PLASMA, BY REGION, 2021-2029 (USD MILLION)
    • TABLE 228 NORTH AMERICA: IN VITRO DIAGNOSTICS MARKET FOR BLOOD, SERUM, AND PLASMA, BY COUNTRY, 2021-2029 (USD MILLION)
    • TABLE 229 EUROPE: IN VITRO DIAGNOSTICS MARKET FOR BLOOD, SERUM, AND PLASMA, BY COUNTRY, 2021-2029 (USD MILLION)
    • TABLE 230 ASIA PACIFIC: IN VITRO DIAGNOSTICS MARKET FOR BLOOD, SERUM, AND PLASMA, BY COUNTRY, 2021-2029 (USD MILLION)
    • TABLE 231 LATIN AMERICA: IN VITRO DIAGNOSTICS MARKET FOR BLOOD, SERUM, AND PLASMA, BY COUNTRY, 2021-2029 (USD MILLION)
    • TABLE 232 GCC COUNTRIES: IN VITRO DIAGNOSTICS MARKET FOR BLOOD, SERUM, AND PLASMA, BY COUNTRY, 2021-2029 (USD MILLION)
  • 8.3 SALIVA
    • 8.3.1 ADVANCEMENTS IN IMMUNOASSAY-BASED TESTS TO SUPPORT MARKET GROWTH
    • TABLE 233 IN VITRO DIAGNOSTICS MARKET FOR SALIVA, BY REGION, 2021-2029 (USD MILLION)
    • TABLE 234 NORTH AMERICA: IN VITRO DIAGNOSTICS MARKET FOR SALIVA, BY COUNTRY, 2021-2029 (USD MILLION)
    • TABLE 235 EUROPE: IN VITRO DIAGNOSTICS MARKET FOR SALIVA, BY COUNTRY, 2021-2029 (USD MILLION)
    • TABLE 236 ASIA PACIFIC: IN VITRO DIAGNOSTICS MARKET FOR SALIVA, BY COUNTRY, 2021-2029 (USD MILLION)
    • TABLE 237 LATIN AMERICA: IN VITRO DIAGNOSTICS MARKET FOR SALIVA, BY COUNTRY, 2021-2029 (USD MILLION)
    • TABLE 238 GCC COUNTRIES: IN VITRO DIAGNOSTICS MARKET FOR SALIVA, BY COUNTRY, 2021-2029 (USD MILLION)
  • 8.4 URINE
    • 8.4.1 INCREASING UTILIZATION IN ILLICIT DRUG TESTING TO BOOST DEMAND
    • TABLE 239 IN VITRO DIAGNOSTICS MARKET FOR URINE, BY REGION, 2021-2029 (USD MILLION)
    • TABLE 240 NORTH AMERICA: IN VITRO DIAGNOSTICS MARKET FOR URINE, BY COUNTRY, 2021-2029 (USD MILLION)
    • TABLE 241 EUROPE: IN VITRO DIAGNOSTICS MARKET FOR URINE, BY COUNTRY, 2021-2029 (USD MILLION)
    • TABLE 242 ASIA PACIFIC: IN VITRO DIAGNOSTICS MARKET FOR URINE, BY COUNTRY, 2021-2029 (USD MILLION)
    • TABLE 243 LATIN AMERICA: IN VITRO DIAGNOSTICS MARKET FOR URINE, BY COUNTRY, 2021-2029 (USD MILLION)
    • TABLE 244 GCC COUNTRIES: IN VITRO DIAGNOSTICS MARKET FOR URINE, BY COUNTRY, 2021-2029 (USD MILLION)
  • 8.5 OTHER SPECIMENS
    • TABLE 245 IN VITRO DIAGNOSTICS MARKET FOR OTHER SPECIMENS, BY REGION, 2021-2029 (USD MILLION)
    • TABLE 246 NORTH AMERICA: IN VITRO DIAGNOSTICS MARKET FOR OTHER SPECIMENS, BY COUNTRY, 2021-2029 (USD MILLION)
    • TABLE 247 EUROPE: IN VITRO DIAGNOSTICS MARKET FOR OTHER SPECIMENS, BY COUNTRY, 2021-2029 (USD MILLION)
    • TABLE 248 ASIA PACIFIC: IN VITRO DIAGNOSTICS MARKET FOR OTHER SPECIMENS, BY COUNTRY, 2021-2029 (USD MILLION)
    • TABLE 249 LATIN AMERICA: IN VITRO DIAGNOSTICS MARKET FOR OTHER SPECIMENS, BY COUNTRY, 2021-2029 (USD MILLION)
    • TABLE 250 GCC COUNTRIES: IN VITRO DIAGNOSTICS MARKET FOR OTHER SPECIMENS, BY COUNTRY, 2021-2029 (USD MILLION)

9 IN VITRO DIAGNOSTICS MARKET, BY TEST TYPE

  • 9.1 INTRODUCTION
    • TABLE 251 IN VITRO DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2029 (USD MILLION)
  • 9.2 LABORATORY TESTS
    • 9.2.1 ADVANCEMENTS IN DIAGNOSTIC TECHNOLOGIES AND GROWING FOCUS ON EARLY DISEASE DETECTION TO PROPEL MARKET
    • TABLE 252 IN VITRO DIAGNOSTICS MARKET FOR LABORATORY TESTS, BY REGION, 2021-2029 (USD MILLION)
    • TABLE 253 NORTH AMERICA: IN VITRO DIAGNOSTICS MARKET FOR LABORATORY TESTS, BY COUNTRY, 2021-2029 (USD MILLION)
    • TABLE 254 EUROPE: IN VITRO DIAGNOSTICS MARKET FOR LABORATORY TESTS, BY COUNTRY, 2021-2029 (USD MILLION)
    • TABLE 255 ASIA PACIFIC: IN VITRO DIAGNOSTICS MARKET FOR LABORATORY TESTS, BY COUNTRY, 2021-2029 (USD MILLION)
    • TABLE 256 LATIN AMERICA: IN VITRO DIAGNOSTICS MARKET FOR LABORATORY TESTS, BY COUNTRY, 2021-2029 (USD MILLION)
    • TABLE 257 GCC COUNTRIES: IN VITRO DIAGNOSTICS MARKET FOR LABORATORY TESTS, BY COUNTRY, 2021-2029 (USD MILLION)
  • 9.3 POINT-OF-CARE TESTS
    • 9.3.1 RAPID RESULTS AND HIGH CONVENIENCE TO BOOST DEMAND
    • TABLE 258 IN VITRO DIAGNOSTICS MARKET FOR POC TESTS, BY REGION, 2021-2029 (USD MILLION)
    • TABLE 259 NORTH AMERICA: IN VITRO DIAGNOSTICS MARKET FOR POC TESTS, BY COUNTRY, 2021-2029 (USD MILLION)
    • TABLE 260 EUROPE: IN VITRO DIAGNOSTICS MARKET FOR POC TESTS, BY COUNTRY, 2021-2029 (USD MILLION)
    • TABLE 261 ASIA PACIFIC: IN VITRO DIAGNOSTICS MARKET FOR POC TESTS, BY COUNTRY, 2021-2029 (USD MILLION)
    • TABLE 262 LATIN AMERICA: IN VITRO DIAGNOSTICS MARKET FOR POC TESTS, BY COUNTRY, 2021-2029 (USD MILLION)
    • TABLE 263 GCC COUNTRIES: IN VITRO DIAGNOSTICS MARKET FOR POC TESTS, BY COUNTRY, 2021-2029 (USD MILLION)

10 IN VITRO DIAGNOSTICS MARKET, BY APPLICATION

  • 10.1 INTRODUCTION
    • TABLE 264 IN VITRO DIAGNOSTICS MARKET, BY APPLICATION, 2021-2029 (USD MILLION)
  • 10.2 INFECTIOUS DISEASES
    • 10.2.1 INCREASING PREVALENCE OF TB AND TYPHOID TO BOOST DEMAND
    • TABLE 265 IN VITRO DIAGNOSTICS MARKET FOR INFECTIOUS DISEASES, BY REGION, 2021-2029 (USD MILLION)
    • TABLE 266 NORTH AMERICA: IN VITRO DIAGNOSTICS MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2021-2029 (USD MILLION)
    • TABLE 267 EUROPE: IN VITRO DIAGNOSTICS MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2021-2029 (USD MILLION)
    • TABLE 268 ASIA PACIFIC: IN VITRO DIAGNOSTICS MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2021-2029 (USD MILLION)
    • TABLE 269 LATIN AMERICA: IN VITRO DIAGNOSTICS MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2021-2029 (USD MILLION)
    • TABLE 270 GCC COUNTRIES: IN VITRO DIAGNOSTICS MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2021-2029 (USD MILLION)
  • 10.3 ONCOLOGY
    • 10.3.1 HIGH INCIDENCE OF BREAST CANCER TO PROPEL MARKET
    • TABLE 271 INCREASING INCIDENCE OF CANCER, BY REGION, 2022 VS. 2040
    • TABLE 272 IN VITRO DIAGNOSTICS MARKET FOR ONCOLOGY, BY REGION, 2021-2029 (USD MILLION)
    • TABLE 273 NORTH AMERICA: IN VITRO DIAGNOSTICS MARKET FOR ONCOLOGY, BY COUNTRY, 2021-2029 (USD MILLION)
    • TABLE 274 EUROPE: IN VITRO DIAGNOSTICS MARKET FOR ONCOLOGY, BY COUNTRY, 2021-2029 (USD MILLION)
    • TABLE 275 ASIA PACIFIC: IN VITRO DIAGNOSTICS MARKET FOR ONCOLOGY, BY COUNTRY, 2021-2029 (USD MILLION)
    • TABLE 276 LATIN AMERICA: IN VITRO DIAGNOSTICS MARKET FOR ONCOLOGY, BY COUNTRY, 2021-2029 (USD MILLION)
    • TABLE 277 GCC COUNTRIES: IN VITRO DIAGNOSTICS MARKET FOR ONCOLOGY, BY COUNTRY, 2021-2029 (USD MILLION)
  • 10.4 ENDOCRINOLOGY
    • 10.4.1 RISING PREVALENCE OF DIABETES AND THYROID-RELATED DISORDERS TO DRIVE MARKET
    • TABLE 278 IN VITRO DIAGNOSTICS MARKET FOR ENDOCRINOLOGY, BY REGION, 2021-2029 (USD MILLION)
    • TABLE 279 NORTH AMERICA: IN VITRO DIAGNOSTICS MARKET FOR ENDOCRINOLOGY, BY COUNTRY, 2021-2029 (USD MILLION)
    • TABLE 280 EUROPE: IN VITRO DIAGNOSTICS MARKET FOR ENDOCRINOLOGY, BY COUNTRY, 2021-2029 (USD MILLION)
    • TABLE 281 ASIA PACIFIC: IN VITRO DIAGNOSTICS MARKET FOR ENDOCRINOLOGY, BY COUNTRY, 2021-2029 (USD MILLION)
    • TABLE 282 LATIN AMERICA: IN VITRO DIAGNOSTICS MARKET FOR ENDOCRINOLOGY, BY COUNTRY, 2021-2029 (USD MILLION)
    • TABLE 283 GCC COUNTRIES: IN VITRO DIAGNOSTICS MARKET FOR ENDOCRINOLOGY, BY COUNTRY, 2021-2029 (USD MILLION)
  • 10.5 CARDIOLOGY
    • 10.5.1 INCREASING USE OF IMMUNOASSAYS IN CVD DETECTION TO FUEL MARKET
    • TABLE 284 IN VITRO DIAGNOSTICS MARKET FOR CARDIOLOGY, BY REGION, 2021-2029 (USD MILLION)
    • TABLE 285 NORTH AMERICA: IN VITRO DIAGNOSTICS MARKET FOR CARDIOLOGY, BY COUNTRY, 2021-2029 (USD MILLION)
    • TABLE 286 EUROPE: IN VITRO DIAGNOSTICS MARKET FOR CARDIOLOGY, BY COUNTRY, 2021-2029 (USD MILLION)
    • TABLE 287 ASIA PACIFIC: IN VITRO DIAGNOSTICS MARKET FOR CARDIOLOGY, BY COUNTRY, 2021-2029 (USD MILLION)
    • TABLE 288 LATIN AMERICA: IN VITRO DIAGNOSTICS MARKET FOR CARDIOLOGY, BY COUNTRY, 2021-2029 (USD MILLION)
    • TABLE 289 GCC COUNTRIES: IN VITRO DIAGNOSTICS MARKET FOR CARDIOLOGY, BY COUNTRY, 2021-2029 (USD MILLION)
  • 10.6 BLOOD SCREENING
    • 10.6.1 RISING INCIDENCE OF HIV AND SYPHILIS TO SUPPORT MARKET GROWTH
    • TABLE 290 IN VITRO DIAGNOSTICS MARKET FOR BLOOD SCREENING, BY REGION, 2021-2029 (USD MILLION)
    • TABLE 291 NORTH AMERICA: IN VITRO DIAGNOSTICS MARKET FOR BLOOD SCREENING, BY COUNTRY, 2021-2029 (USD MILLION)
    • TABLE 292 EUROPE: IN VITRO DIAGNOSTICS MARKET FOR BLOOD SCREENING, BY COUNTRY, 2021-2029 (USD MILLION)
    • TABLE 293 ASIA PACIFIC: IN VITRO DIAGNOSTICS MARKET FOR BLOOD SCREENING, BY COUNTRY, 2021-2029 (USD MILLION)
    • TABLE 294 LATIN AMERICA: IN VITRO DIAGNOSTICS MARKET FOR BLOOD SCREENING, BY COUNTRY, 2021-2029 (USD MILLION)
    • TABLE 295 GCC COUNTRIES: IN VITRO DIAGNOSTICS MARKET FOR BLOOD SCREENING, BY COUNTRY, 2021-2029 (USD MILLION)
  • 10.7 GENETIC TESTING
    • 10.7.1 DIAGNOSIS OF RARE DISEASES TO SUPPORT MARKET GROWTH
    • TABLE 296 IN VITRO DIAGNOSTICS MARKET FOR GENETIC TESTING, BY REGION, 2021-2029 (USD MILLION)
    • TABLE 297 NORTH AMERICA: IN VITRO DIAGNOSTICS MARKET FOR GENETIC TESTING, BY COUNTRY, 2021-2029 (USD MILLION)
    • TABLE 298 EUROPE: IN VITRO DIAGNOSTICS MARKET FOR GENETIC TESTING, BY COUNTRY, 2021-2029 (USD MILLION)
    • TABLE 299 ASIA PACIFIC: IN VITRO DIAGNOSTICS MARKET FOR GENETIC TESTING, BY COUNTRY, 2021-2029 (USD MILLION)
    • TABLE 300 LATIN AMERICA: IN VITRO DIAGNOSTICS MARKET FOR GENETIC TESTING, BY COUNTRY, 2021-2029 (USD MILLION)
    • TABLE 301 GCC COUNTRIES: IN VITRO DIAGNOSTICS MARKET FOR GENETIC TESTING, BY COUNTRY, 2021-2029 (USD MILLION)
  • 10.8 AUTOIMMUNE DISEASES
    • 10.8.1 GROWING DEMAND FOR AUTOIMMUNITY ASSAYS TO DRIVE MARKET
    • TABLE 302 IN VITRO DIAGNOSTICS MARKET FOR AUTOIMMUNE DISEASES, BY REGION, 2021-2029 (USD MILLION)
    • TABLE 303 NORTH AMERICA: IN VITRO DIAGNOSTICS MARKET FOR AUTOIMMUNE DISEASES, BY COUNTRY, 2021-2029 (USD MILLION)
    • TABLE 304 EUROPE: IN VITRO DIAGNOSTICS MARKET FOR AUTOIMMUNE DISEASES, BY COUNTRY, 2021-2029 (USD MILLION)
    • TABLE 305 ASIA PACIFIC: IN VITRO DIAGNOSTICS MARKET FOR AUTOIMMUNE DISEASES, BY COUNTRY, 2021-2029 (USD MILLION)
    • TABLE 306 LATIN AMERICA: IN VITRO DIAGNOSTICS MARKET FOR AUTOIMMUNE DISEASES, BY COUNTRY, 2021-2029 (USD MILLION)
    • TABLE 307 GCC COUNTRIES: IN VITRO DIAGNOSTICS MARKET FOR AUTOIMMUNE DISEASES, BY COUNTRY, 2021-2029 (USD MILLION)
  • 10.9 ALLERGY DIAGNOSTICS
    • 10.9.1 ABILITY TO DETERMINE FOOD & DRUG ALLERGIES TO SUPPORT MARKET GROWTH
    • TABLE 308 IN VITRO DIAGNOSTICS MARKET FOR ALLERGY DIAGNOSTICS, BY REGION, 2021-2029 (USD MILLION)
    • TABLE 309 NORTH AMERICA: IN VITRO DIAGNOSTICS MARKET FOR ALLERGY DIAGNOSTICS, BY COUNTRY, 2021-2029 (USD MILLION)
    • TABLE 310 EUROPE: IN VITRO DIAGNOSTICS MARKET FOR ALLERGY DIAGNOSTICS, BY COUNTRY, 2021-2029 (USD MILLION)
    • TABLE 311 ASIA PACIFIC: IN VITRO DIAGNOSTICS MARKET FOR ALLERGY DIAGNOSTICS, BY COUNTRY, 2021-2029 (USD MILLION)
    • TABLE 312 LATIN AMERICA: IN VITRO DIAGNOSTICS MARKET FOR ALLERGY DIAGNOSTICS, BY COUNTRY, 2021-2029 (USD MILLION)
    • TABLE 313 GCC COUNTRIES: IN VITRO DIAGNOSTICS MARKET FOR ALLERGY DIAGNOSTICS, BY COUNTRY, 2021-2029 (USD MILLION)
  • 10.10 DRUG MONITORING & TESTING
    • 10.10.1 INCREASING ILLICIT DRUG CONSUMPTION TO DRIVE MARKET
    • TABLE 314 KEY PRODUCTS FOR DRUG MONITORING
    • TABLE 315 KEY IVD PRODUCTS FOR DRUG TESTING
    • TABLE 316 IN VITRO DIAGNOSTICS MARKET FOR DRUG MONITORING & TESTING, BY REGION, 2021-2029 (USD MILLION)
    • TABLE 317 NORTH AMERICA: IN VITRO DIAGNOSTICS MARKET FOR DRUG MONITORING & TESTING, BY COUNTRY, 2021-2029 (USD MILLION)
    • TABLE 318 EUROPE: IN VITRO DIAGNOSTICS MARKET FOR DRUG MONITORING & TESTING, BY COUNTRY, 2021-2029 (USD MILLION)
    • TABLE 319 ASIA PACIFIC: IN VITRO DIAGNOSTICS MARKET FOR DRUG MONITORING & TESTING, BY COUNTRY, 2021-2029 (USD MILLION)
    • TABLE 320 LATIN AMERICA: IN VITRO DIAGNOSTICS MARKET FOR DRUG MONITORING & TESTING, BY COUNTRY, 2021-2029 (USD MILLION)
    • TABLE 321 GCC COUNTRIES: IN VITRO DIAGNOSTICS MARKET FOR DRUG MONITORING & TESTING, BY COUNTRY, 2021-2029 (USD MILLION)
  • 10.11 BONE & MINERAL DISORDERS
    • 10.11.1 RISING CASES OF OSTEOPOROSIS TO FUEL MARKET
    • TABLE 322 KEY PRODUCTS FOR BONE & MINERAL DISORDERS
    • TABLE 323 IN VITRO DIAGNOSTICS MARKET FOR BONE & MINERAL DISORDERS, BY REGION, 2021-2029 (USD MILLION)
    • TABLE 324 NORTH AMERICA: IN VITRO DIAGNOSTICS MARKET FOR BONE & MINERAL DISORDERS, BY COUNTRY, 2021-2029 (USD MILLION)
    • TABLE 325 EUROPE: IN VITRO DIAGNOSTICS MARKET FOR BONE & MINERAL DISORDERS, BY COUNTRY, 2021-2029 (USD MILLION)
    • TABLE 326 ASIA PACIFIC: IN VITRO DIAGNOSTICS MARKET FOR BONE & MINERAL DISORDERS, BY COUNTRY, 2021-2029 (USD MILLION)
    • TABLE 327 LATIN AMERICA: IN VITRO DIAGNOSTICS MARKET FOR BONE & MINERAL DISORDERS, BY COUNTRY, 2021-2029 (USD MILLION)
    • TABLE 328 GCC COUNTRIES: IN VITRO DIAGNOSTICS MARKET FOR BONE & MINERAL DISORDERS, BY COUNTRY, 2021-2029 (USD MILLION)
  • 10.12 COAGULATION TESTING
    • 10.12.1 INCREASING PREVALENCE OF HEMOPHILIA TO BOOST DEMAND
    • TABLE 329 IN VITRO DIAGNOSTICS MARKET FOR COAGULATION TESTING, BY REGION, 2021-2029 (USD MILLION)
    • TABLE 330 NORTH AMERICA: IN VITRO DIAGNOSTICS MARKET FOR COAGULATION TESTING, BY COUNTRY, 2021-2029 (USD MILLION)
    • TABLE 331 EUROPE: IN VITRO DIAGNOSTICS MARKET FOR COAGULATION TESTING, BY COUNTRY, 2021-2029 (USD MILLION)
    • TABLE 332 ASIA PACIFIC: IN VITRO DIAGNOSTICS MARKET FOR COAGULATION TESTING, BY COUNTRY, 2021-2029 (USD MILLION)
    • TABLE 333 LATIN AMERICA: IN VITRO DIAGNOSTICS MARKET FOR COAGULATION TESTING, BY COUNTRY, 2021-2029 (USD MILLION)
    • TABLE 334 GCC COUNTRIES: IN VITRO DIAGNOSTICS MARKET FOR COAGULATION TESTING, BY COUNTRY, 2021-2029 (USD MILLION)
  • 10.13 BLOOD GROUP TYPING
    • 10.13.1 RISING NUMBER OF SURGICAL PROCEDURES TO SUPPORT MARKET DEMAND
    • TABLE 335 IN VITRO DIAGNOSTICS MARKET FOR BLOOD GROUP TYPING, BY REGION, 2021-2029 (USD MILLION)
    • TABLE 336 NORTH AMERICA: IN VITRO DIAGNOSTICS MARKET FOR BLOOD GROUP TYPING, BY COUNTRY, 2021-2029 (USD MILLION)
    • TABLE 337 EUROPE: IN VITRO DIAGNOSTICS MARKET FOR BLOOD GROUP TYPING, BY COUNTRY, 2021-2029 (USD MILLION)
    • TABLE 338 ASIA PACIFIC: IN VITRO DIAGNOSTICS MARKET FOR BLOOD GROUP TYPING, BY COUNTRY, 2021-2029 (USD MILLION)
    • TABLE 339 LATIN AMERICA: IN VITRO DIAGNOSTICS MARKET FOR BLOOD GROUP TYPING, BY COUNTRY, 2021-2029 (USD MILLION)
    • TABLE 340 GCC COUNTRIES: IN VITRO DIAGNOSTICS MARKET FOR BLOOD GROUP TYPING, BY COUNTRY, 2021-2029 (USD MILLION)
  • 10.14 OTHER APPLICATIONS
    • TABLE 341 IN VITRO DIAGNOSTICS MARKET FOR OTHER APPLICATIONS, BY REGION, 2021-2029 (USD MILLION)
    • TABLE 342 NORTH AMERICA: IN VITRO DIAGNOSTICS MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2021-2029 (USD MILLION)
    • TABLE 343 EUROPE: IN VITRO DIAGNOSTICS MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2021-2029 (USD MILLION)
    • TABLE 344 ASIA PACIFIC: IN VITRO DIAGNOSTICS MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2021-2029 (USD MILLION)
    • TABLE 345 LATIN AMERICA: IN VITRO DIAGNOSTICS MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2021-2029 (USD MILLION)
    • TABLE 346 GCC COUNTRIES: IN VITRO DIAGNOSTICS MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2021-2029 (USD MILLION)

11 IN VITRO DIAGNOSTICS MARKET, BY END USER

  • 11.1 INTRODUCTION
    • TABLE 347 IN VITRO DIAGNOSTICS MARKET, BY END USER, 2021-2029 (USD MILLION)
  • 11.2 HOSPITALS & CLINICS
    • 11.2.1 RISING INCIDENCE OF CHRONIC DISEASES TO BOOST DEMAND
    • TABLE 348 IN VITRO DIAGNOSTICS MARKET FOR HOSPITALS & CLINICS, BY REGION, 2021-2029 (USD MILLION)
    • TABLE 349 NORTH AMERICA: IN VITRO DIAGNOSTICS MARKET FOR HOSPITALS & CLINICS, BY COUNTRY, 2021-2029 (USD MILLION)
    • TABLE 350 EUROPE: IN VITRO DIAGNOSTICS MARKET FOR HOSPITALS & CLINICS, BY COUNTRY, 2021-2029 (USD MILLION)
    • TABLE 351 ASIA PACIFIC: IN VITRO DIAGNOSTICS MARKET FOR HOSPITALS & CLINICS, BY COUNTRY, 2021-2029 (USD MILLION)
    • TABLE 352 LATIN AMERICA: IN VITRO DIAGNOSTICS MARKET FOR HOSPITALS & CLINICS, BY COUNTRY, 2021-2029 (USD MILLION)
    • TABLE 353 GCC COUNTRIES: IN VITRO DIAGNOSTICS MARKET FOR HOSPITALS & CLINICS, BY COUNTRY, 2021-2029 (USD MILLION)
  • 11.3 CLINICAL LABORATORIES
    • TABLE 354 IN VITRO DIAGNOSTICS MARKET FOR CLINICAL LABORATORIES, BY TYPE, 2021-2029 (USD MILLION)
    • TABLE 355 IN VITRO DIAGNOSTICS MARKET FOR CLINICAL LABORATORIES, BY REGION, 2021-2029 (USD MILLION)
    • TABLE 356 NORTH AMERICA: IN VITRO DIAGNOSTICS MARKET FOR CLINICAL LABORATORIES, BY COUNTRY, 2021-2029 (USD MILLION)
    • TABLE 357 EUROPE: IN VITRO DIAGNOSTICS MARKET FOR CLINICAL LABORATORIES, BY COUNTRY, 2021-2029 (USD MILLION)
    • TABLE 358 ASIA PACIFIC: IN VITRO DIAGNOSTICS MARKET FOR CLINICAL LABORATORIES, BY COUNTRY, 2021-2029 (USD MILLION)
    • TABLE 359 LATIN AMERICA: IN VITRO DIAGNOSTICS MARKET FOR CLINICAL LABORATORIES, BY COUNTRY, 2021-2029 (USD MILLION)
    • TABLE 360 GCC COUNTRIES: IN VITRO DIAGNOSTICS MARKET FOR CLINICAL LABORATORIES, BY COUNTRY, 2021-2029 (USD MILLION)
    • 11.3.1 LARGE REFERENCE LABORATORIES
      • 11.3.1.1 Capability to conduct specific advanced tests to propel market
    • TABLE 361 IN VITRO DIAGNOSTICS MARKET FOR LARGE REFERENCE LABORATORIES, BY REGION, 2021-2029 (USD MILLION)
    • TABLE 362 NORTH AMERICA: IN VITRO DIAGNOSTICS MARKET FOR LARGE REFERENCE LABORATORIES, BY COUNTRY, 2021-2029 (USD MILLION)
    • TABLE 363 EUROPE: IN VITRO DIAGNOSTICS MARKET FOR LARGE REFERENCE LABORATORIES, BY COUNTRY, 2021-2029 (USD MILLION)
    • TABLE 364 ASIA PACIFIC: IN VITRO DIAGNOSTICS MARKET FOR LARGE REFERENCE LABORATORIES, BY COUNTRY, 2021-2029 (USD MILLION)
    • TABLE 365 LATIN AMERICA: IN VITRO DIAGNOSTICS MARKET FOR LARGE REFERENCE LABORATORIES, BY COUNTRY, 2021-2029 (USD MILLION)
    • TABLE 366 GCC COUNTRIES: IN VITRO DIAGNOSTICS MARKET FOR LARGE REFERENCE LABORATORIES, BY COUNTRY, 2021-2029 (USD MILLION)
    • 11.3.2 SMALL AND MEDIUM-SIZED LABORATORIES
      • 11.3.2.1 Growing focus on POC device adoption to support market growth
    • TABLE 367 IN VITRO DIAGNOSTICS MARKET FOR SMALL AND MEDIUM-SIZED LABORATORIES, BY REGION, 2021-2029 (USD MILLION)
    • TABLE 368 NORTH AMERICA: IN VITRO DIAGNOSTICS MARKET FOR SMALL AND MEDIUM-SIZED LABORATORIES, BY COUNTRY, 2021-2029 (USD MILLION)
    • TABLE 369 EUROPE: IN VITRO DIAGNOSTICS MARKET FOR SMALL AND MEDIUM-SIZED LABORATORIES, BY COUNTRY, 2021-2029 (USD MILLION)
    • TABLE 370 ASIA PACIFIC: IN VITRO DIAGNOSTICS MARKET FOR SMALL AND MEDIUM-SIZED LABORATORIES, BY COUNTRY, 2021-2029 (USD MILLION)
    • TABLE 371 LATIN AMERICA: IN VITRO DIAGNOSTICS MARKET FOR SMALL AND MEDIUM-SIZED LABORATORIES, BY COUNTRY, 2021-2029 (USD MILLION)
    • TABLE 372 GCC COUNTRIES: IN VITRO DIAGNOSTICS MARKET FOR SMALL AND MEDIUM-SIZED LABORATORIES, BY COUNTRY, 2021-2029 (USD MILLION)
  • 11.4 BLOOD BANKS
    • 11.4.1 RISING UTILIZATION OF ELISA TESTS TO PROPEL MARKET
    • TABLE 373 IN VITRO DIAGNOSTICS MARKET FOR BLOOD BANKS, BY REGION, 2021-2029 (USD MILLION)
    • TABLE 374 NORTH AMERICA: IN VITRO DIAGNOSTICS MARKET FOR BLOOD BANKS, BY COUNTRY, 2021-2029 (USD MILLION)
    • TABLE 375 EUROPE: IN VITRO DIAGNOSTICS MARKET FOR BLOOD BANKS, BY COUNTRY, 2021-2029 (USD MILLION)
    • TABLE 376 ASIA PACIFIC: IN VITRO DIAGNOSTICS MARKET FOR BLOOD BANKS, BY COUNTRY, 2021-2029 (USD MILLION)
    • TABLE 377 LATIN AMERICA: IN VITRO DIAGNOSTICS MARKET FOR BLOOD BANKS, BY COUNTRY, 2021-2029 (USD MILLION)
    • TABLE 378 GCC COUNTRIES: IN VITRO DIAGNOSTICS MARKET FOR BLOOD BANKS, BY COUNTRY, 2021-2029 (USD MILLION)
  • 11.5 HOME CARE SETTINGS
    • 11.5.1 ADOPTION OF CONVENIENT AT-HOME ANTIGEN TESTS TO BOOST DEMAND
    • TABLE 379 IN VITRO DIAGNOSTICS MARKET FOR HOME CARE SETTINGS, BY REGION, 2021-2029 (USD MILLION)
    • TABLE 380 NORTH AMERICA: IN VITRO DIAGNOSTICS MARKET FOR HOME CARE SETTINGS, BY COUNTRY, 2021-2029 (USD MILLION)
    • TABLE 381 EUROPE: IVD MARKET FOR HOME CARE SETTINGS, BY COUNTRY, 2021-2029 (USD MILLION)
    • TABLE 382 ASIA PACIFIC: IN VITRO DIAGNOSTICS MARKET FOR HOME CARE SETTINGS, BY COUNTRY, 2021-2029 (USD MILLION)
    • TABLE 383 LATIN AMERICA: IN VITRO DIAGNOSTICS MARKET FOR HOME CARE SETTINGS, BY COUNTRY, 2021-2029 (USD MILLION)
    • TABLE 384 GCC COUNTRIES: IN VITRO DIAGNOSTICS MARKET FOR HOME CARE SETTINGS, BY COUNTRY, 2021-2029 (USD MILLION)
  • 11.6 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES
    • 11.6.1 INCREASING FOCUS ON DRUG DISCOVERY DEVELOPMENT TO DRIVE MARKET
    • TABLE 385 IN VITRO DIAGNOSTICS MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY REGION, 2021-2029 (USD MILLION)
    • TABLE 386 NORTH AMERICA: IN VITRO DIAGNOSTICS MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2021-2029 (USD MILLION)
    • TABLE 387 EUROPE: IN VITRO DIAGNOSTICS MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2021-2029 (USD MILLION)
    • TABLE 388 ASIA PACIFIC: IVD MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2021-2029 (USD MILLION)
    • TABLE 389 LATIN AMERICA: IN VITRO DIAGNOSTICS MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2021-2029 (USD MILLION)
    • TABLE 390 GCC COUNTRIES: IN VITRO DIAGNOSTICS MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2021-2029 (USD MILLION)
  • 11.7 ACADEMIC INSTITUTES
    • 11.7.1 RISING INDUSTRY-ACADEMIA COLLABORATIONS FOR PRODUCT DEVELOPMENT TO SUPPORT MARKET GROWTH
    • TABLE 391 IN VITRO DIAGNOSTICS MARKET FOR ACADEMIC INSTITUTES, BY REGION, 2021-2029 (USD MILLION)
    • TABLE 392 NORTH AMERICA: IVD MARKET FOR ACADEMIC INSTITUTES, BY COUNTRY, 2021-2029 (USD MILLION)
    • TABLE 393 EUROPE: IN VITRO DIAGNOSTICS MARKET FOR ACADEMIC INSTITUTES, BY COUNTRY, 2021-2029 (USD MILLION)
    • TABLE 394 ASIA PACIFIC: IN VITRO DIAGNOSTICS MARKET FOR ACADEMIC INSTITUTES, BY COUNTRY, 2021-2029 (USD MILLION)
    • TABLE 395 LATIN AMERICA: IN VITRO DIAGNOSTICS MARKET FOR ACADEMIC INSTITUTES, BY COUNTRY, 2021-2029 (USD MILLION)
    • TABLE 396 GCC COUNTRIES: IN VITRO DIAGNOSTICS MARKET FOR ACADEMIC INSTITUTES, BY COUNTRY, 2021-2029 (USD MILLION)
  • 11.8 OTHER END USERS
    • TABLE 397 IN VITRO DIAGNOSTICS MARKET FOR OTHER END USERS, BY REGION, 2021-2029 (USD MILLION)
    • TABLE 398 NORTH AMERICA: IN VITRO DIAGNOSTICS MARKET FOR OTHER END USERS, BY COUNTRY, 2021-2029 (USD MILLION)
    • TABLE 399 EUROPE: IN VITRO DIAGNOSTICS MARKET FOR OTHER END USERS, BY COUNTRY, 2021-2029 (USD MILLION)
    • TABLE 400 ASIA PACIFIC: IN VITRO DIAGNOSTICS MARKET FOR OTHER END USERS, BY COUNTRY, 2021-2029 (USD MILLION)
    • TABLE 401 LATIN AMERICA: IN VITRO DIAGNOSTICS MARKET FOR OTHER END USERS, BY COUNTRY, 2021-2029 (USD MILLION)
    • TABLE 402 GCC COUNTRIES: IN VITRO DIAGNOSTICS MARKET FOR OTHER END USERS, BY COUNTRY, 2021-2029 (USD MILLION)

12 IN VITRO DIAGNOSTICS MARKET, BY REGION

  • 12.1 INTRODUCTION
    • TABLE 403 IN VITRO DIAGNOSTICS MARKET, BY REGION, 2021-2029 (USD MILLION)
  • 12.2 NORTH AMERICA
    • 12.2.1 NORTH AMERICA: RECESSION IMPACT
    • FIGURE 34 NORTH AMERICA: IN VITRO DIAGNOSTICS MARKET SNAPSHOT
    • TABLE 404 NORTH AMERICA: IN VITRO DIAGNOSTICS MARKET, BY COUNTRY, 2021-2029 (USD MILLION)
    • TABLE 405 NORTH AMERICA: IN VITRO DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2021-2029 (USD MILLION)
    • TABLE 406 NORTH AMERICA: IN VITRO DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021-2029 (USD MILLION)
    • TABLE 407 NORTH AMERICA: IN VITRO DIAGNOSTICS MARKET FOR IMMUNOASSAYS, BY TYPE, 2021-2029 (USD MILLION)
    • TABLE 408 NORTH AMERICA: IN VITRO DIAGNOSTICS MARKET FOR CLINICAL CHEMISTRY, BY TYPE, 2021-2029 (USD MILLION)
    • TABLE 409 NORTH AMERICA: IN VITRO DIAGNOSTICS MARKET FOR MOLECULAR DIAGNOSTICS, BY TYPE, 2021-2029 (USD MILLION)
    • TABLE 410 NORTH AMERICA: IN VITRO DIAGNOSTICS MARKET, BY SPECIMEN, 2021-2029 (USD MILLION)
    • TABLE 411 NORTH AMERICA: IN VITRO DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2029 (USD MILLION)
    • TABLE 412 NORTH AMERICA: IN VITRO DIAGNOSTICS MARKET, BY APPLICATION, 2021-2029 (USD MILLION)
    • TABLE 413 NORTH AMERICA: IN VITRO DIAGNOSTICS MARKET, BY END USER, 2021-2029 (USD MILLION)
    • TABLE 414 NORTH AMERICA: IN VITRO DIAGNOSTICS MARKET FOR CLINICAL LABORATORIES, BY TYPE, 2021-2029 (USD MILLION)
    • 12.2.2 US
      • 12.2.2.1 Established reimbursement framework and favorable policies for IVD providers to drive market
    • TABLE 415 US: MACROECONOMIC INDICATORS
    • TABLE 416 US: NUMBER OF IN VITRO TESTS CONDUCTED (BILLION)
    • TABLE 417 US: IN VITRO DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2021-2029 (USD MILLION)
    • TABLE 418 US: IN VITRO DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021-2029 (USD MILLION)
    • TABLE 419 US: IN VITRO DIAGNOSTICS MARKET FOR IMMUNOASSAYS, BY TYPE, 2021-2029 (USD MILLION)
    • TABLE 420 US: IN VITRO DIAGNOSTICS MARKET FOR CLINICAL CHEMISTRY, BY TYPE, 2021-2029 (USD MILLION)
    • TABLE 421 US: IN VITRO DIAGNOSTICS MARKET FOR MOLECULAR DIAGNOSTICS, BY TYPE, 2021-2029 (USD MILLION)
    • TABLE 422 US: IN VITRO DIAGNOSTICS MARKET, BY SPECIMEN, 2021-2029 (USD MILLION)
    • TABLE 423 US: IN VITRO DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2029 (USD MILLION)
    • TABLE 424 US: IN VITRO DIAGNOSTICS MARKET, BY APPLICATION, 2021-2029 (USD MILLION)
    • TABLE 425 US: IN VITRO DIAGNOSTICS MARKET, BY END USER, 2021-2029 (USD MILLION)
    • TABLE 426 US: IN VITRO DIAGNOSTICS MARKET FOR CLINICAL LABORATORIES, BY TYPE, 2021-2029 (USD MILLION)
    • 12.2.3 CANADA
      • 12.2.3.1 Favorable funding initiatives for early disease diagnosis to drive market
    • TABLE 427 CANADA: ESTIMATED PREVALENCE OF DIABETES
    • TABLE 428 CANADA: MACROECONOMIC INDICATORS
    • TABLE 429 CANADA: IN VITRO DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2021-2029 (USD MILLION)
    • TABLE 430 CANADA: IN VITRO DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021-2029 (USD MILLION)
    • TABLE 431 CANADA: IN VITRO DIAGNOSTICS MARKET FOR IMMUNOASSAYS, BY TYPE, 2021-2029 (USD MILLION)
    • TABLE 432 CANADA: IN VITRO DIAGNOSTICS MARKET FOR CLINICAL CHEMISTRY, BY TYPE, 2021-2029 (USD MILLION)
    • TABLE 433 CANADA: IN VITRO DIAGNOSTICS MARKET FOR MOLECULAR DIAGNOSTICS, BY TYPE, 2021-2029 (USD MILLION)
    • TABLE 434 CANADA: IN VITRO DIAGNOSTICS MARKET, BY SPECIMEN, 2021-2029 (USD MILLION)
    • TABLE 435 CANADA: IN VITRO DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2029 (USD MILLION)
    • TABLE 436 CANADA: IN VITRO DIAGNOSTICS MARKET, BY APPLICATION, 2021-2029 (USD MILLION)
    • TABLE 437 CANADA: IN VITRO DIAGNOSTICS MARKET, BY END USER, 2021-2029 (USD MILLION)
    • TABLE 438 CANADA: IN VITRO DIAGNOSTICS MARKET FOR CLINICAL LABORATORIES, BY TYPE, 2021-2029 (USD MILLION)
  • 12.3 EUROPE
    • 12.3.1 EUROPE: RECESSION IMPACT
    • TABLE 439 EUROPE: IN VITRO DIAGNOSTICS MARKET, BY COUNTRY, 2021-2029 (USD MILLION)
    • TABLE 440 EUROPE: IN VITRO DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2021-2029 (USD MILLION)
    • TABLE 441 EUROPE: IN VITRO DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021-2029 (USD MILLION)
    • TABLE 442 EUROPE: IN VITRO DIAGNOSTICS MARKET FOR IMMUNOASSAYS, BY TYPE, 2021-2029 (USD MILLION)
    • TABLE 443 EUROPE: IN VITRO DIAGNOSTICS MARKET FOR CLINICAL CHEMISTRY, BY TYPE, 2021-2029 (USD MILLION)
    • TABLE 444 EUROPE: IN VITRO DIAGNOSTICS MARKET FOR MOLECULAR DIAGNOSTICS, BY TYPE, 2021-2029 (USD MILLION)
    • TABLE 445 EUROPE: IN VITRO DIAGNOSTICS MARKET, BY SPECIMEN, 2021-2029 (USD MILLION)
    • TABLE 446 EUROPE: IN VITRO DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2029 (USD MILLION)
    • TABLE 447 EUROPE: IN VITRO DIAGNOSTICS MARKET, BY APPLICATION, 2021-2029 (USD MILLION)
    • TABLE 448 EUROPE: IN VITRO DIAGNOSTICS MARKET, BY END USER, 2021-2029 (USD MILLION)
    • TABLE 449 EUROPE: IN VITRO DIAGNOSTICS MARKET FOR CLINICAL LABORATORIES, BY TYPE, 2021-2029 (USD MILLION)
    • 12.3.2 GERMANY
      • 12.3.2.1 Increasing investments in clinical diagnostics research to drive market
    • TABLE 450 GERMANY: IN VITRO DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2021-2029 (USD MILLION)
    • TABLE 451 GERMANY: IN VITRO DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021-2029 (USD MILLION)
    • TABLE 452 GERMANY: IN VITRO DIAGNOSTICS MARKET FOR IMMUNOASSAYS, BY TYPE, 2021-2029 (USD MILLION)
    • TABLE 453 GERMANY: IN VITRO DIAGNOSTICS MARKET FOR CLINICAL CHEMISTRY, BY TYPE, 2021-2029 (USD MILLION)
    • TABLE 454 GERMANY: IN VITRO DIAGNOSTICS MARKET FOR MOLECULAR DIAGNOSTICS, BY TYPE, 2021-2029 (USD MILLION)
    • TABLE 455 GERMANY: IN VITRO DIAGNOSTICS MARKET, BY SPECIMEN, 2021-2029 (USD MILLION)
    • TABLE 456 GERMANY: IN VITRO DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2029 (USD MILLION)
    • TABLE 457 GERMANY: IN VITRO DIAGNOSTICS MARKET, BY APPLICATION, 2021-2029 (USD MILLION)
    • TABLE 458 GERMANY: IN VITRO DIAGNOSTICS MARKET, BY END USER, 2021-2029 (USD MILLION)
    • TABLE 459 GERMANY: IN VITRO DIAGNOSTICS MARKET FOR CLINICAL LABORATORIES, BY TYPE, 2021-2029 (USD MILLION)
    • 12.3.3 FRANCE
      • 12.3.3.1 High healthcare expenditure and rising investments in genomic medicine to drive market
    • TABLE 460 FRANCE: IN VITRO DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2021-2029 (USD MILLION)
    • TABLE 461 FRANCE: IN VITRO DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021-2029 (USD MILLION)
    • TABLE 462 FRANCE: IN VITRO DIAGNOSTICS MARKET FOR IMMUNOASSAYS, BY TYPE, 2021-2029 (USD MILLION)
    • TABLE 463 FRANCE: IN VITRO DIAGNOSTICS MARKET FOR CLINICAL CHEMISTRY, BY TYPE, 2021-2029 (USD MILLION)
    • TABLE 464 FRANCE: IN VITRO DIAGNOSTICS MARKET FOR MOLECULAR DIAGNOSTICS, BY TYPE, 2021-2029 (USD MILLION)
    • TABLE 465 FRANCE: IN VITRO DIAGNOSTICS MARKET, BY SPECIMEN, 2021-2029 (USD MILLION)
    • TABLE 466 FRANCE: IN VITRO DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2029 (USD MILLION)
    • TABLE 467 FRANCE: IN VITRO DIAGNOSTICS MARKET, BY APPLICATION, 2021-2029 (USD MILLION)
    • TABLE 468 FRANCE: IN VITRO DIAGNOSTICS MARKET, BY END USER, 2021-2029 (USD MILLION)
    • TABLE 469 FRANCE: IN VITRO DIAGNOSTICS MARKET FOR CLINICAL LABORATORIES, BY TYPE, 2021-2029 (USD MILLION)
    • 12.3.4 UK
      • 12.3.4.1 Rising adoption of genome-based testing to drive market
    • TABLE 470 UK: MACROECONOMIC INDICATORS
    • TABLE 471 UK: IN VITRO DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2021-2029 (USD MILLION)
    • TABLE 472 UK: IN VITRO DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021-2029 (USD MILLION)
    • TABLE 473 UK: IN VITRO DIAGNOSTICS MARKET FOR IMMUNOASSAYS, BY TYPE, 2021-2029 (USD MILLION)
    • TABLE 474 UK: IN VITRO DIAGNOSTICS MARKET FOR CLINICAL CHEMISTRY, BY TYPE, 2021-2029 (USD MILLION)
    • TABLE 475 UK: IN VITRO DIAGNOSTICS MARKET FOR MOLECULAR DIAGNOSTICS, BY TYPE, 2021-2029 (USD MILLION)
    • TABLE 476 UK: IN VITRO DIAGNOSTICS MARKET, BY SPECIMEN, 2021-2029 (USD MILLION)
    • TABLE 477 UK: IN VITRO DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2029 (USD MILLION)
    • TABLE 478 UK: IN VITRO DIAGNOSTICS MARKET, BY APPLICATION, 2021-2029 (USD MILLION)
    • TABLE 479 UK: IN VITRO DIAGNOSTICS MARKET, BY END USER, 2021-2029 (USD MILLION)
    • TABLE 480 UK: IN VITRO DIAGNOSTICS MARKET FOR CLINICAL LABORATORIES, BY TYPE, 2021-2029 (USD MILLION)
    • 12.3.5 ITALY
      • 12.3.5.1 Growing geriatric population and subsequent rise in chronic conditions to support market growth
    • TABLE 481 ITALY: IN VITRO DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2021-2029 (USD MILLION)
    • TABLE 482 ITALY: IN VITRO DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021-2029 (USD MILLION)
    • TABLE 483 ITALY: IN VITRO DIAGNOSTICS MARKET FOR IMMUNOASSAYS, BY TYPE, 2021-2029 (USD MILLION)
    • TABLE 484 ITALY: IN VITRO DIAGNOSTICS MARKET FOR CLINICAL CHEMISTRY, BY TYPE, 2021-2029 (USD MILLION)
    • TABLE 485 ITALY: IN VITRO DIAGNOSTICS MARKET FOR MOLECULAR DIAGNOSTICS, BY TYPE, 2021-2029 (USD MILLION)
    • TABLE 486 ITALY: IN VITRO DIAGNOSTICS MARKET, BY SPECIMEN, 2021-2029 (USD MILLION)
    • TABLE 487 ITALY: IN VITRO DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2029 (USD MILLION)
    • TABLE 488 ITALY: IN VITRO DIAGNOSTICS MARKET, BY APPLICATION, 2021-2029 (USD MILLION)
    • TABLE 489 ITALY: IN VITRO DIAGNOSTICS MARKET, BY END USER, 2021-2029 (USD MILLION)
    • TABLE 490 ITALY: IN VITRO DIAGNOSTICS MARKET FOR CLINICAL LABORATORIES, BY TYPE, 2021-2029 (USD MILLION)
    • 12.3.6 SPAIN
      • 12.3.6.1 Rising adoption of technologically advanced immunoassay systems to drive market
    • TABLE 491 SPAIN: IN VITRO DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2021-2029 (USD MILLION)
    • TABLE 492 SPAIN: IN VITRO DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021-2029 (USD MILLION)
    • TABLE 493 SPAIN: IN VITRO DIAGNOSTICS MARKET FOR IMMUNOASSAYS, BY TYPE, 2021-2029 (USD MILLION)
    • TABLE 494 SPAIN: IN VITRO DIAGNOSTICS MARKET FOR CLINICAL CHEMISTRY, BY TYPE, 2021-2029 (USD MILLION)
    • TABLE 495 SPAIN: IN VITRO DIAGNOSTICS MARKET FOR MOLECULAR DIAGNOSTICS, BY TYPE, 2021-2029 (USD MILLION)
    • TABLE 496 SPAIN: IN VITRO DIAGNOSTICS MARKET, BY SPECIMEN, 2021-2029 (USD MILLION)
    • TABLE 497 SPAIN: IN VITRO DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2029 (USD MILLION)
    • TABLE 498 SPAIN: IN VITRO DIAGNOSTICS MARKET, BY APPLICATION, 2021-2029 (USD MILLION)
    • TABLE 499 SPAIN: IN VITRO DIAGNOSTICS MARKET, BY END USER, 2021-2029 (USD MILLION)
    • TABLE 500 SPAIN: IN VITRO DIAGNOSTICS MARKET FOR CLINICAL LABORATORIES, BY TYPE, 2021-2029 (USD MILLION)
    • 12.3.7 RUSSIA
      • 12.3.7.1 High incidence of respiratory infectious diseases to boost demand
    • TABLE 501 RUSSIA: MACROECONOMIC INDICATORS
    • TABLE 502 RUSSIA: IN VITRO DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2021-2029 (USD MILLION)
    • TABLE 503 RUSSIA: IN VITRO DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021-2029 (USD MILLION)
    • TABLE 504 RUSSIA: IN VITRO DIAGNOSTICS MARKET FOR IMMUNOASSAYS, BY TYPE, 2021-2029 (USD MILLION)
    • TABLE 505 RUSSIA: IN VITRO DIAGNOSTICS MARKET FOR CLINICAL CHEMISTRY, BY TYPE, 2021-2029 (USD MILLION)
    • TABLE 506 RUSSIA: IN VITRO DIAGNOSTICS MARKET FOR MOLECULAR DIAGNOSTICS, BY TYPE, 2021-2029 (USD MILLION)
    • TABLE 507 RUSSIA: IN VITRO DIAGNOSTICS MARKET, BY SPECIMEN, 2021-2029 (USD MILLION)
    • TABLE 508 RUSSIA: IN VITRO DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2029 (USD MILLION)
    • TABLE 509 RUSSIA: IN VITRO DIAGNOSTICS MARKET, BY APPLICATION, 2021-2029 (USD MILLION)
    • TABLE 510 RUSSIA: IN VITRO DIAGNOSTICS MARKET, BY END USER, 2021-2029 (USD MILLION)
    • TABLE 511 RUSSIA: IN VITRO DIAGNOSTICS MARKET FOR CLINICAL LABORATORIES, BY TYPE, 2021-2029 (USD MILLION)
    • 12.3.8 SWITZERLAND
      • 12.3.8.1 Rising prevalence of chronic diseases to support market growth
    • TABLE 512 SWITZERLAND: MACROECONOMIC INDICATORS
    • TABLE 513 SWITZERLAND: IN VITRO DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2021-2029 (USD MILLION)
    • TABLE 514 SWITZERLAND: IN VITRO DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021-2029 (USD MILLION)
    • TABLE 515 SWITZERLAND: IN VITRO DIAGNOSTICS MARKET FOR IMMUNOASSAYS, BY TYPE, 2021-2029 (USD MILLION)
    • TABLE 516 SWITZERLAND: IN VITRO DIAGNOSTICS MARKET FOR CLINICAL CHEMISTRY, BY TYPE, 2021-2029 (USD MILLION)
    • TABLE 517 SWITZERLAND: IN VITRO DIAGNOSTICS MARKET FOR MOLECULAR DIAGNOSTICS, BY TYPE, 2021-2029 (USD MILLION)
    • TABLE 518 SWITZERLAND: IN VITRO DIAGNOSTICS MARKET, BY SPECIMEN, 2021-2029 (USD MILLION)
    • TABLE 519 SWITZERLAND: IN VITRO DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2029 (USD MILLION)
    • TABLE 520 SWITZERLAND: IN VITRO DIAGNOSTICS MARKET, BY APPLICATION, 2021-2029 (USD MILLION)
    • TABLE 521 SWITZERLAND: IN VITRO DIAGNOSTICS MARKET, BY END USER, 2021-2029 (USD MILLION)
    • TABLE 522 SWITZERLAND: IN VITRO DIAGNOSTICS MARKET FOR CLINICAL LABORATORIES, BY TYPE, 2021-2029 (USD MILLION)
    • 12.3.9 REST OF EUROPE
    • TABLE 523 REST OF EUROPE: IN VITRO DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2021-2029 (USD MILLION)
    • TABLE 524 REST OF EUROPE: IN VITRO DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021-2029 (USD MILLION)
    • TABLE 525 REST OF EUROPE: IN VITRO DIAGNOSTICS MARKET FOR IMMUNOASSAYS, BY TYPE, 2021-2029 (USD MILLION)
    • TABLE 526 REST OF EUROPE: IN VITRO DIAGNOSTICS MARKET FOR CLINICAL CHEMISTRY, BY TYPE, 2021-2029 (USD MILLION)
    • TABLE 527 REST OF EUROPE: IN VITRO DIAGNOSTICS MARKET FOR MOLECULAR DIAGNOSTICS, BY TYPE, 2021-2029 (USD MILLION)
    • TABLE 528 REST OF EUROPE: IN VITRO DIAGNOSTICS MARKET, BY SPECIMEN, 2021-2029 (USD MILLION)
    • TABLE 529 REST OF EUROPE: IN VITRO DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2029 (USD MILLION)
    • TABLE 530 REST OF EUROPE: IN VITRO DIAGNOSTICS MARKET, BY APPLICATION, 2021-2029 (USD MILLION)
    • TABLE 531 REST OF EUROPE: IN VITRO DIAGNOSTICS MARKET, BY END USER, 2021-2029 (USD MILLION)
    • TABLE 532 REST OF EUROPE: IN VITRO DIAGNOSTICS MARKET FOR CLINICAL LABORATORIES, BY TYPE, 2021-2029 (USD MILLION)
  • 12.4 ASIA PACIFIC
    • FIGURE 35 ASIA PACIFIC: IN VITRO DIAGNOSTICS MARKET SNAPSHOT
    • TABLE 533 ASIA PACIFIC: IN VITRO DIAGNOSTICS MARKET, BY COUNTRY, 2021-2029 (USD MILLION)
    • TABLE 534 ASIA PACIFIC: IN VITRO DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2021-2029 (USD MILLION)
    • TABLE 535 ASIA PACIFIC: IN VITRO DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021-2029 (USD MILLION)
    • TABLE 536 ASIA PACIFIC: IN VITRO DIAGNOSTICS MARKET FOR IMMUNOASSAYS, BY TYPE, 2021-2029 (USD MILLION)
    • TABLE 537 ASIA PACIFIC: IN VITRO DIAGNOSTICS MARKET FOR CLINICAL CHEMISTRY, BY TYPE, 2021-2029 (USD MILLION)
    • TABLE 538 ASIA PACIFIC: IN VITRO DIAGNOSTICS MARKET FOR MOLECULAR DIAGNOSTICS, BY TYPE, 2021-2029 (USD MILLION)
    • TABLE 539 ASIA PACIFIC: IN VITRO DIAGNOSTICS MARKET, BY SPECIMEN, 2021-2029 (USD MILLION)
    • TABLE 540 ASIA PACIFIC: IN VITRO DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2029 (USD MILLION)
    • TABLE 541 ASIA PACIFIC: IN VITRO DIAGNOSTICS MARKET, BY APPLICATION, 2021-2029 (USD MILLION)
    • TABLE 542 ASIA PACIFIC: IN VITRO DIAGNOSTICS MARKET, BY END USER, 2021-2029 (USD MILLION)
    • TABLE 543 ASIA PACIFIC: IN VITRO DIAGNOSTICS MARKET FOR CLINICAL LABORATORIES, BY TYPE, 2021-2029 (USD MILLION)
    • 12.4.1 ASIA PACIFIC: RECESSION IMPACT
    • 12.4.2 JAPAN
      • 12.4.2.1 Increasing research investments for immunoassays to drive market
    • TABLE 544 JAPAN: MACROECONOMIC INDICATORS
    • TABLE 545 JAPAN: IN VITRO DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2021-2029 (USD MILLION)
    • TABLE 546 JAPAN: IN VITRO DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021-2029 (USD MILLION)
    • TABLE 547 JAPAN: IN VITRO DIAGNOSTICS MARKET FOR IMMUNOASSAYS, BY TYPE, 2021-2029 (USD MILLION)
    • TABLE 548 JAPAN: IN VITRO DIAGNOSTICS MARKET FOR CLINICAL CHEMISTRY, BY TYPE, 2021-2029 (USD MILLION)
    • TABLE 549 JAPAN: IN VITRO DIAGNOSTICS MARKET FOR MOLECULAR DIAGNOSTICS, BY TYPE, 2021-2029 (USD MILLION)
    • TABLE 550 JAPAN: IN VITRO DIAGNOSTICS MARKET, BY SPECIMEN, 2021-2029 (USD MILLION)
    • TABLE 551 JAPAN: IN VITRO DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2029 (USD MILLION)
    • TABLE 552 JAPAN: IN VITRO DIAGNOSTICS MARKET, BY APPLICATION, 2021-2029 (USD MILLION)
    • TABLE 553 JAPAN: IN VITRO DIAGNOSTICS MARKET, BY END USER, 2021-2029 (USD MILLION)
    • TABLE 554 JAPAN: IN VITRO DIAGNOSTICS MARKET FOR CLINICAL LABORATORIES, BY TYPE, 2021-2029 (USD MILLION)
    • 12.4.3 CHINA
      • 12.4.3.1 Growing focus on preventive care to boost demand
    • TABLE 555 CHINA: MACROECONOMIC INDICATORS
    • TABLE 556 CHINA: IN VITRO DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2021-2029 (USD MILLION)
    • TABLE 557 CHINA: IN VITRO DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021-2029 (USD MILLION)
    • TABLE 558 CHINA: IN VITRO DIAGNOSTICS MARKET FOR IMMUNOASSAYS, BY TYPE, 2021-2029 (USD MILLION)
    • TABLE 559 CHINA: IN VITRO DIAGNOSTICS MARKET FOR CLINICAL CHEMISTRY, BY TYPE, 2021-2029 (USD MILLION)
    • TABLE 560 CHINA: IN VITRO DIAGNOSTICS MARKET FOR MOLECULAR DIAGNOSTICS, BY TYPE, 2021-2029 (USD MILLION)
    • TABLE 561 CHINA: IN VITRO DIAGNOSTICS MARKET, BY SPECIMEN, 2021-2029 (USD MILLION)
    • TABLE 562 CHINA: IN VITRO DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2029 (USD MILLION)
    • TABLE 563 CHINA: IN VITRO DIAGNOSTICS MARKET, BY APPLICATION, 2021-2029 (USD MILLION)
    • TABLE 564 CHINA: IN VITRO DIAGNOSTICS MARKET, BY END USER, 2021-2029 (USD MILLION)
    • TABLE 565 CHINA: IN VITRO DIAGNOSTICS MARKET FOR CLINICAL LABORATORIES, BY TYPE, 2021-2029 (USD MILLION)
    • 12.4.4 INDIA
      • 12.4.4.1 Rising incidence of diabetes and cancer to drive market
    • TABLE 566 INDIA: MACROECONOMIC INDICATORS
    • TABLE 567 INDIA: IN VITRO DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2021-2029 (USD MILLION)
    • TABLE 568 INDIA: IN VITRO DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021-2029 (USD MILLION)
    • TABLE 569 INDIA: IN VITRO DIAGNOSTICS MARKET FOR IMMUNOASSAYS, BY TYPE, 2021-2029 (USD MILLION)
    • TABLE 570 INDIA: IN VITRO DIAGNOSTICS MARKET FOR CLINICAL CHEMISTRY, BY TYPE, 2021-2029 (USD MILLION)
    • TABLE 571 INDIA: IN VITRO DIAGNOSTICS MARKET FOR MOLECULAR DIAGNOSTICS, BY TYPE, 2021-2029 (USD MILLION)
    • TABLE 572 INDIA: IN VITRO DIAGNOSTICS MARKET, BY SPECIMEN, 2021-2029 (USD MILLION)
    • TABLE 573 INDIA: IN VITRO DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2029 (USD MILLION)
    • TABLE 574 INDIA: IN VITRO DIAGNOSTICS MARKET, BY APPLICATION, 2021-2029 (USD MILLION)
    • TABLE 575 INDIA: IN VITRO DIAGNOSTICS MARKET, BY END USER, 2021-2029 (USD MILLION)
    • TABLE 576 INDIA: IN VITRO DIAGNOSTICS MARKET FOR CLINICAL LABORATORIES, BY TYPE, 2021-2029 (USD MILLION)
    • 12.4.5 SOUTH KOREA
      • 12.4.5.1 Rising healthcare spending for innovative IVD technologies to support market growth
    • TABLE 577 SOUTH KOREA: MACROECONOMIC INDICATORS
    • TABLE 578 SOUTH KOREA: IN VITRO DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2021-2029 (USD MILLION)
    • TABLE 579 SOUTH KOREA: IN VITRO DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021-2029 (USD MILLION)
    • TABLE 580 SOUTH KOREA: IN VITRO DIAGNOSTICS MARKET FOR IMMUNOASSAYS, BY TYPE, 2021-2029 (USD MILLION)
    • TABLE 581 SOUTH KOREA: IN VITRO DIAGNOSTICS MARKET FOR CLINICAL CHEMISTRY, BY TYPE, 2021-2029 (USD MILLION)
    • TABLE 582 SOUTH KOREA: IN VITRO DIAGNOSTICS MARKET FOR MOLECULAR DIAGNOSTICS, BY TYPE, 2021-2029 (USD MILLION)
    • TABLE 583 SOUTH KOREA: IN VITRO DIAGNOSTICS MARKET, BY SPECIMEN, 2021-2029 (USD MILLION)
    • TABLE 584 SOUTH KOREA: IN VITRO DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2029 (USD MILLION)
    • TABLE 585 SOUTH KOREA: IN VITRO DIAGNOSTICS MARKET, BY APPLICATION, 2021-2029 (USD MILLION)
    • TABLE 586 SOUTH KOREA: IN VITRO DIAGNOSTICS MARKET, BY END USER, 2021-2029 (USD MILLION)
    • TABLE 587 SOUTH KOREA: IN VITRO DIAGNOSTICS MARKET FOR CLINICAL LABORATORIES, BY TYPE, 2021-2029 (USD MILLION)
    • 12.4.6 AUSTRALIA
      • 12.4.6.1 Increasing incidence of chronic diseases and rising blood donations to fuel market
    • TABLE 588 AUSTRALIA: MACROECONOMIC INDICATORS
    • TABLE 589 AUSTRALIA: IN VITRO DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2021-2029 (USD MILLION)
    • TABLE 590 AUSTRALIA: IN VITRO DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021-2029 (USD MILLION)
    • TABLE 591 AUSTRALIA: IN VITRO DIAGNOSTICS MARKET FOR IMMUNOASSAYS, BY TYPE, 2021-2029 (USD MILLION)
    • TABLE 592 AUSTRALIA: IN VITRO DIAGNOSTICS MARKET FOR CLINICAL CHEMISTRY, BY TYPE, 2021-2029 (USD MILLION)
    • TABLE 593 AUSTRALIA: IN VITRO DIAGNOSTICS MARKET FOR MOLECULAR DIAGNOSTICS, BY TYPE, 2021-2029 (USD MILLION)
    • TABLE 594 AUSTRALIA: IN VITRO DIAGNOSTICS MARKET, BY SPECIMEN, 2021-2029 (USD MILLION)
    • TABLE 595 AUSTRALIA: IN VITRO DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2029 (USD MILLION)
    • TABLE 596 AUSTRALIA: IN VITRO DIAGNOSTICS MARKET, BY APPLICATION, 2021-2029 (USD MILLION)
    • TABLE 597 AUSTRALIA: IN VITRO DIAGNOSTICS MARKET, BY END USER, 2021-2029 (USD MILLION)
    • TABLE 598 AUSTRALIA: IN VITRO DIAGNOSTICS MARKET FOR CLINICAL LABORATORIES, BY TYPE, 2021-2029 (USD MILLION)
    • 12.4.7 REST OF ASIA PACIFIC
    • TABLE 599 REST OF ASIA PACIFIC: IN VITRO DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2021-2029 (USD MILLION)
    • TABLE 600 REST OF ASIA PACIFIC: IN VITRO DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021-2029 (USD MILLION)
    • TABLE 601 REST OF ASIA PACIFIC: IN VITRO DIAGNOSTICS MARKET FOR IMMUNOASSAYS, BY TYPE, 2021-2029 (USD MILLION)
    • TABLE 602 REST OF ASIA PACIFIC: IN VITRO DIAGNOSTICS MARKET FOR CLINICAL CHEMISTRY, BY TYPE, 2021-2029 (USD MILLION)
    • TABLE 603 REST OF ASIA PACIFIC: IN VITRO DIAGNOSTICS MARKET FOR MOLECULAR DIAGNOSTICS, BY TYPE, 2021-2029 (USD MILLION)
    • TABLE 604 REST OF ASIA PACIFIC: IN VITRO DIAGNOSTICS MARKET, BY SPECIMEN, 2021-2029 (USD MILLION)
    • TABLE 605 REST OF ASIA PACIFIC: IN VITRO DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2029 (USD MILLION)
    • TABLE 606 REST OF ASIA PACIFIC: IN VITRO DIAGNOSTICS MARKET, BY APPLICATION, 2021-2029 (USD MILLION)
    • TABLE 607 REST OF ASIA PACIFIC: IN VITRO DIAGNOSTICS MARKET, BY END USER, 2021-2029 (USD MILLION)
    • TABLE 608 REST OF ASIA PACIFIC: IN VITRO DIAGNOSTICS MARKET FOR CLINICAL LABORATORIES, BY TYPE, 2021-2029 (USD MILLION)
  • 12.5 LATIN AMERICA
    • 12.5.1 LATIN AMERICA: RECESSION IMPACT
    • TABLE 609 LATIN AMERICA: IN VITRO DIAGNOSTICS MARKET, BY COUNTRY, 2021-2029 (USD MILLION)
    • TABLE 610 LATIN AMERICA: IN VITRO DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2021-2029 (USD MILLION)
    • TABLE 611 LATIN AMERICA: IN VITRO DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021-2029 (USD MILLION)
    • TABLE 612 LATIN AMERICA: IN VITRO DIAGNOSTICS MARKET FOR IMMUNOASSAYS, BY TYPE, 2021-2029 (USD MILLION)
    • TABLE 613 LATIN AMERICA: IN VITRO DIAGNOSTICS MARKET FOR CLINICAL CHEMISTRY, BY TYPE, 2021-2029 (USD MILLION)
    • TABLE 614 LATIN AMERICA: IN VITRO DIAGNOSTICS MARKET FOR MOLECULAR DIAGNOSTICS, BY TYPE, 2021-2029 (USD MILLION)
    • TABLE 615 LATIN AMERICA: IN VITRO DIAGNOSTICS MARKET, BY SPECIMEN, 2021-2029 (USD MILLION)
    • TABLE 616 LATIN AMERICA: IN VITRO DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2029 (USD MILLION)
    • TABLE 617 LATIN AMERICA: IN VITRO DIAGNOSTICS MARKET, BY APPLICATION, 2021-2029 (USD MILLION)
    • TABLE 618 LATIN AMERICA: IN VITRO DIAGNOSTICS MARKET, BY END USER, 2021-2029 (USD MILLION)
    • TABLE 619 LATIN AMERICA: IN VITRO DIAGNOSTICS MARKET FOR CLINICAL LABORATORIES, BY TYPE, 2021-2029 (USD MILLION)
    • 12.5.2 BRAZIL
      • 12.5.2.1 Rising prevalence of diabetes to boost demand for IVD products
    • TABLE 620 BRAZIL: MACROECONOMIC INDICATORS
    • TABLE 621 BRAZIL: IN VITRO DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2021-2029 (USD MILLION)
    • TABLE 622 BRAZIL: IN VITRO DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021-2029 (USD MILLION)
    • TABLE 623 BRAZIL: IN VITRO DIAGNOSTICS MARKET FOR IMMUNOASSAYS, BY TYPE, 2021-2029 (USD MILLION)
    • TABLE 624 BRAZIL: IN VITRO DIAGNOSTICS MARKET FOR CLINICAL CHEMISTRY, BY TYPE, 2021-2029 (USD MILLION)
    • TABLE 625 BRAZIL: IN VITRO DIAGNOSTICS MARKET FOR MOLECULAR DIAGNOSTICS, BY TYPE, 2021-2029 (USD MILLION)
    • TABLE 626 BRAZIL: IN VITRO DIAGNOSTICS MARKET, BY SPECIMEN, 2021-2029 (USD MILLION)
    • TABLE 627 BRAZIL: IN VITRO DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2029 (USD MILLION)
    • TABLE 628 BRAZIL: IN VITRO DIAGNOSTICS MARKET, BY APPLICATION, 2021-2029 (USD MILLION)
    • TABLE 629 BRAZIL: IN VITRO DIAGNOSTICS MARKET, BY END USER, 2021-2029 (USD MILLION)
    • TABLE 630 BRAZIL: IN VITRO DIAGNOSTICS MARKET FOR CLINICAL LABORATORIES, BY TYPE, 2021-2029 (USD MILLION)
    • 12.5.3 MEXICO
      • 12.5.3.1 Establishment of clinical laboratories to fuel uptake
    • TABLE 631 MEXICO: MACROECONOMIC INDICATORS
    • TABLE 632 MEXICO: IN VITRO DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2021-2029 (USD MILLION)
    • TABLE 633 MEXICO: IN VITRO DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021-2029 (USD MILLION)
    • TABLE 634 MEXICO: IN VITRO DIAGNOSTICS MARKET FOR IMMUNOASSAYS, BY TYPE, 2021-2029 (USD MILLION)
    • TABLE 635 MEXICO: IN VITRO DIAGNOSTICS MARKET FOR CLINICAL CHEMISTRY, BY TYPE, 2021-2029 (USD MILLION)
    • TABLE 636 MEXICO: IN VITRO DIAGNOSTICS MARKET FOR MOLECULAR DIAGNOSTICS, BY TYPE, 2021-2029 (USD MILLION)
    • TABLE 637 MEXICO: IN VITRO DIAGNOSTICS MARKET, BY SPECIMEN, 2021-2029 (USD MILLION)
    • TABLE 638 MEXICO: IN VITRO DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2029 (USD MILLION)
    • TABLE 639 MEXICO: IN VITRO DIAGNOSTICS MARKET, BY APPLICATION, 2021-2029 (USD MILLION)
    • TABLE 640 MEXICO: IN VITRO DIAGNOSTICS MARKET, BY END USER, 2021-2029 (USD MILLION)
    • TABLE 641 MEXICO: IN VITRO DIAGNOSTICS MARKET FOR CLINICAL LABORATORIES, BY TYPE, 2021-2029 (USD MILLION)
    • 12.5.4 REST OF LATIN AMERICA
    • TABLE 642 REST OF LATIN AMERICA: IN VITRO DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2021-2029 (USD MILLION)
    • TABLE 643 REST OF LATIN AMERICA: IN VITRO DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021-2029 (USD MILLION)
    • TABLE 644 REST OF LATIN AMERICA: IN VITRO DIAGNOSTICS MARKET FOR IMMUNOASSAYS, BY TYPE, 2021-2029 (USD MILLION)
    • TABLE 645 REST OF LATIN AMERICA: IN VITRO DIAGNOSTICS MARKET FOR CLINICAL CHEMISTRY, BY TYPE, 2021-2029 (USD MILLION)
    • TABLE 646 REST OF LATIN AMERICA: IN VITRO DIAGNOSTICS MARKET FOR MOLECULAR DIAGNOSTICS, BY TYPE, 2021-2029 (USD MILLION)
    • TABLE 647 REST OF LATIN AMERICA: IN VITRO DIAGNOSTICS MARKET, BY SPECIMEN, 2021-2029 (USD MILLION)
    • TABLE 648 REST OF LATIN AMERICA: IN VITRO DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2029 (USD MILLION)
    • TABLE 649 REST OF LATIN AMERICA: IN VITRO DIAGNOSTICS MARKET, BY APPLICATION, 2021-2029 (USD MILLION)
    • TABLE 650 REST OF LATIN AMERICA: IN VITRO DIAGNOSTICS MARKET, BY END USER, 2021-2029 (USD MILLION)
    • TABLE 651 REST OF LATIN AMERICA: IN VITRO DIAGNOSTICS MARKET FOR CLINICAL LABORATORIES, BY TYPE, 2021-2029 (USD MILLION)
  • 12.6 MIDDLE EAST & AFRICA
    • 12.6.1 GROWING FOCUS ON PRENATAL & CANCER TESTING TO DRIVE MARKET
    • TABLE 652 MIDDLE EAST & AFRICA: IN VITRO DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2021-2029 (USD MILLION)
    • TABLE 653 MIDDLE EAST & AFRICA: IN VITRO DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021-2029 (USD MILLION)
    • TABLE 654 MIDDLE EAST & AFRICA: IN VITRO DIAGNOSTICS MARKET FOR IMMUNOASSAYS, BY TYPE, 2021-2029 (USD MILLION)
    • TABLE 655 MIDDLE EAST & AFRICA: IN VITRO DIAGNOSTICS MARKET FOR CLINICAL CHEMISTRY, BY TYPE, 2021-2029 (USD MILLION)
    • TABLE 656 MIDDLE EAST & AFRICA: IN VITRO DIAGNOSTICS MARKET FOR MOLECULAR DIAGNOSTICS, BY TYPE, 2021-2029 (USD MILLION)
    • TABLE 657 MIDDLE EAST & AFRICA: IN VITRO DIAGNOSTICS MARKET, BY SPECIMEN, 2021-2029 (USD MILLION)
    • TABLE 658 MIDDLE EAST & AFRICA: IN VITRO DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2029 (USD MILLION)
    • TABLE 659 MIDDLE EAST & AFRICA: IN VITRO DIAGNOSTICS MARKET, BY APPLICATION, 2021-2029 (USD MILLION)
    • TABLE 660 MIDDLE EAST & AFRICA: IN VITRO DIAGNOSTICS MARKET, BY END USER, 2021-2029 (USD MILLION)
    • TABLE 661 MIDDLE EAST & AFRICA: IN VITRO DIAGNOSTICS MARKET FOR CLINICAL LABORATORIES, BY TYPE, 2021-2029 (USD MILLION)
    • 12.6.2 MIDDLE EAST & AFRICA: RECESSION IMPACT
  • 12.7 GCC COUNTRIES
    • 12.7.1 GCC COUNTRIES: RECESSION IMPACT
    • TABLE 662 GCC COUNTRIES: IN VITRO DIAGNOSTICS MARKET, BY COUNTRY, 2021-2029 (USD MILLION)
    • TABLE 663 GCC COUNTRIES: IN VITRO DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2021-2029 (USD MILLION)
    • TABLE 664 GCC COUNTRIES: IN VITRO DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021-2029 (USD MILLION)
    • TABLE 665 GCC COUNTRIES: IN VITRO DIAGNOSTICS MARKET FOR IMMUNOASSAYS, BY TYPE, 2021-2029 (USD MILLION)
    • TABLE 666 GCC COUNTRIES: IN VITRO DIAGNOSTICS MARKET FOR CLINICAL CHEMISTRY, BY TYPE, 2021-2029 (USD MILLION)
    • TABLE 667 GCC COUNTRIES: IN VITRO DIAGNOSTICS MARKET FOR MOLECULAR DIAGNOSTICS, BY TYPE, 2021-2029 (USD MILLION)
    • TABLE 668 GCC COUNTRIES: IN VITRO DIAGNOSTICS MARKET, BY SPECIMEN, 2021-2029 (USD MILLION)
    • TABLE 669 GCC COUNTRIES: IN VITRO DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2029 (USD MILLION)
    • TABLE 670 GCC COUNTRIES: IN VITRO DIAGNOSTICS MARKET, BY APPLICATION, 2021-2029 (USD MILLION)
    • TABLE 671 GCC COUNTRIES: IN VITRO DIAGNOSTICS MARKET, BY END USER, 2021-2029 (USD MILLION)
    • TABLE 672 GCC COUNTRIES: IN VITRO DIAGNOSTICS MARKET FOR CLINICAL LABORATORIES, BY TYPE, 2021-2029 (USD MILLION)
    • 12.7.2 KINGDOM OF SAUDI ARABIA (KSA)
      • 12.7.2.1 Rising government healthcare expenditure to boost demand
    • TABLE 673 KINGDOM OF SAUDI ARABIA: IN VITRO DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2021-2029 (USD MILLION)
    • TABLE 674 KINGDOM OF SAUDI ARABIA: IN VITRO DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021-2029 (USD MILLION)
    • TABLE 675 KINGDOM OF SAUDI ARABIA: IN VITRO DIAGNOSTICS MARKET FOR IMMUNOASSAYS, BY TYPE, 2021-2029 (USD MILLION)
    • TABLE 676 KINGDOM OF SAUDI ARABIA: IN VITRO DIAGNOSTICS MARKET FOR CLINICAL CHEMISTRY, BY TYPE, 2021-2029 (USD MILLION)
    • TABLE 677 KINGDOM OF SAUDI ARABIA: IN VITRO DIAGNOSTICS MARKET FOR MOLECULAR DIAGNOSTICS, BY TYPE, 2021-2029 (USD MILLION)
    • TABLE 678 KINGDOM OF SAUDI ARABIA: IN VITRO DIAGNOSTICS MARKET, BY SPECIMEN, 2021-2029 (USD MILLION)
    • TABLE 679 KINGDOM OF SAUDI ARABIA: IN VITRO DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2029 (USD MILLION)
    • TABLE 680 KINGDOM OF SAUDI ARABIA: IN VITRO DIAGNOSTICS MARKET, BY APPLICATION, 2021-2029 (USD MILLION)
    • TABLE 681 KINGDOM OF SAUDI ARABIA: IN VITRO DIAGNOSTICS MARKET, BY END USER, 2021-2029 (USD MILLION)
    • TABLE 682 KINGDOM OF SAUDI ARABIA: IN VITRO DIAGNOSTICS MARKET FOR CLINICAL LABORATORIES, BY TYPE, 2021-2029 (USD MILLION)
    • 12.7.3 UNITED ARAB EMIRATES (UAE)
      • 12.7.3.1 Improvements in healthcare infrastructure to support market growth
    • TABLE 683 UNITED ARAB EMIRATES: IN VITRO DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2021-2029 (USD MILLION)
    • TABLE 684 UNITED ARAB EMIRATES: IN VITRO DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021-2029 (USD MILLION)
    • TABLE 685 UNITED ARAB EMIRATES: IN VITRO DIAGNOSTICS MARKET FOR IMMUNOASSAYS, BY TYPE, 2021-2029 (USD MILLION)
    • TABLE 686 UNITED ARAB EMIRATES: IN VITRO DIAGNOSTICS MARKET FOR CLINICAL CHEMISTRY, BY TYPE, 2021-2029 (USD MILLION)
    • TABLE 687 UNITED ARAB EMIRATES: IN VITRO DIAGNOSTICS MARKET FOR MOLECULAR DIAGNOSTICS, BY TYPE, 2021-2029 (USD MILLION)
    • TABLE 688 UNITED ARAB EMIRATES: IN VITRO DIAGNOSTICS MARKET, BY SPECIMEN, 2021-2029 (USD MILLION)
    • TABLE 689 UNITED ARAB EMIRATES: IN VITRO DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2029 (USD MILLION)
    • TABLE 690 UNITED ARAB EMIRATES: IN VITRO DIAGNOSTICS MARKET, BY APPLICATION, 2021-2029 (USD MILLION)
    • TABLE 691 UNITED ARAB EMIRATES: IN VITRO DIAGNOSTICS MARKET, BY END USER, 2021-2029 (USD MILLION)
    • TABLE 692 UNITED ARAB EMIRATES: IN VITRO DIAGNOSTICS MARKET FOR CLINICAL LABORATORIES, BY TYPE, 2021-2029 (USD MILLION)
    • 12.7.4 OTHER GCC COUNTRIES
    • TABLE 693 OTHER GCC COUNTRIES: IN VITRO DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2021-2029 (USD MILLION)
    • TABLE 694 OTHER GCC COUNTRIES: IN VITRO DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021-2029 (USD MILLION)
    • TABLE 695 OTHER GCC COUNTRIES: IN VITRO DIAGNOSTICS MARKET FOR IMMUNOASSAYS, BY TYPE, 2021-2029 (USD MILLION)
    • TABLE 696 OTHER GCC COUNTRIES: IN VITRO DIAGNOSTICS MARKET FOR CLINICAL CHEMISTRY, BY TYPE, 2021-2029 (USD MILLION)
    • TABLE 697 OTHER GCC COUNTRIES: IN VITRO DIAGNOSTICS MARKET FOR MOLECULAR DIAGNOSTICS, BY TYPE, 2021-2029 (USD MILLION)
    • TABLE 698 OTHER GCC COUNTRIES: IN VITRO DIAGNOSTICS MARKET, BY SPECIMEN, 2021-2029 (USD MILLION)
    • TABLE 699 OTHER GCC COUNTRIES: IN VITRO DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2029 (USD MILLION)
    • TABLE 700 OTHER GCC COUNTRIES: IN VITRO DIAGNOSTICS MARKET, BY APPLICATION, 2021-2029 (USD MILLION)
    • TABLE 701 OTHER GCC COUNTRIES: IN VITRO DIAGNOSTICS MARKET, BY END USER, 2021-2029 (USD MILLION)
    • TABLE 702 OTHER GCC COUNTRIES: IN VITRO DIAGNOSTICS MARKET FOR CLINICAL LABORATORIES, BY TYPE, 2021-2029 (USD MILLION)

13 COMPETITIVE LANDSCAPE

  • 13.1 OVERVIEW
  • 13.2 STRATEGIES ADOPTED BY KEY PLAYERS
    • TABLE 703 OVERVIEW OF STRATEGIES DEPLOYED BY KEY PLAYERS IN IVD MARKET
  • 13.3 REVENUE SHARE ANALYSIS OF LEADING MARKET PLAYERS
    • FIGURE 36 REVENUE SHARE ANALYSIS OF KEY PLAYERS IN IVD MARKET
  • 13.4 MARKET SHARE ANALYSIS
    • TABLE 704 IN VITRO DIAGNOSTICS MARKET: INTENSITY OF COMPETITIVE RIVALRY
    • FIGURE 37 IN VITRO DIAGNOSTICS MARKET SHARE, BY KEY PLAYER (2023)
  • 13.5 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2023
    • 13.5.1 STARS
    • 13.5.2 EMERGING LEADERS
    • 13.5.3 PERVASIVE PLAYERS
    • 13.5.4 PARTICIPANTS
    • FIGURE 38 COMPANY EVALUATION MATRIX FOR KEY PLAYERS, 2023
    • 13.5.5 COMPANY FOOTPRINT ANALYSIS OF KEY PLAYERS
    • TABLE 705 COMPANY FOOTPRINT ANALYSIS
    • TABLE 706 COMPANY PRODUCT & SERVICE FOOTPRINT
    • TABLE 707 COMPANY TECHNOLOGY FOOTPRINT
    • TABLE 708 COMPANY APPLICATION FOOTPRINT
  • 13.6 START UP/SME EVALUATION MATRIX, 2023
    • 13.6.1 PROGRESSIVE COMPANIES
    • 13.6.2 RESPONSIVE COMPANIES
    • 13.6.3 DYNAMIC COMPANIES
    • 13.6.4 STARTING BLOCKS
    • FIGURE 39 COMPANY EVALUATION MATRIX FOR STARTUPS/SMES, 2023
    • 13.6.5 COMPETITIVE BENCHMARKING OF START-UPS/SMES
    • TABLE 709 IN VITRO DIAGNOSTICS MARKET: KEY START-UPS/SMES
  • 13.7 COMPETITIVE SCENARIO
    • 13.7.1 PRODUCT & SERVICE LAUNCHES AND APPROVALS
    • TABLE 710 IN VITRO DIAGNOSTICS MARKET: PRODUCT & SERVICE LAUNCHES AND APPROVALS (JANUARY 2020-JANUARY 2024)
    • 13.7.2 DEALS
    • TABLE 711 IN VITRO DIAGNOSTICS MARKET: DEALS (JANUARY 2020-JANUARY 2024)
    • 13.7.3 EXPANSIONS
    • TABLE 712 IN VITRO DIAGNOSTICS MARKET: EXPANSIONS (JANUARY 2020-JANUARY 2024)
    • 13.7.4 OTHER DEVELOPMENTS
    • TABLE 713 IN VITRO DIAGNOSTICS MARKET: OTHER DEVELOPMENTS (JANUARY 2020-JANUARY 2024)
  • 13.8 BRAND/PRODUCT COMPARISON
    • TABLE 714 BRAND/PRODUCT COMPARISON FOR IN VITRO DIAGNOSTICS INSTRUMENTS

14 COMPANY PROFILES

  • 14.1 KEY PLAYERS
  • (Business Overview, Products/Solutions/Services Offered, Recent Developments, MnM view (Key strengths/Right to win, Strategic choices made, Weakness/competitive threats)**
    • 14.1.1 DANAHER CORPORATION
    • TABLE 715 DANAHER: COMPANY OVERVIEW
    • FIGURE 40 DANAHER: COMPANY SNAPSHOT (2023)
    • 14.1.2 ROCHE DIAGNOSTICS
    • TABLE 716 ROCHE DIAGNOSTICS: COMPANY OVERVIEW
    • FIGURE 41 ROCHE DIAGNOSTICS: COMPANY SNAPSHOT (2023)
    • 14.1.3 ABBOTT
    • TABLE 717 ABBOTT: COMPANY OVERVIEW
    • FIGURE 42 ABBOTT: COMPANY SNAPSHOT (2023)
    • 14.1.4 SIEMENS HEALTHINEERS AG
    • TABLE 718 SIEMENS HEALTHINEERS AG: COMPANY OVERVIEW
    • FIGURE 43 SIEMENS HEALTHINEERS AG: COMPANY SNAPSHOT (2023)
    • 14.1.5 THERMO FISHER SCIENTIFIC INC.
    • TABLE 719 THERMO FISHER SCIENTIFIC INC.: COMPANY OVERVIEW
    • FIGURE 44 THERMO FISHER SCIENTIFIC INC.: COMPANY SNAPSHOT (2023)
    • 14.1.6 ILLUMINA, INC.
    • TABLE 720 ILLUMINA, INC.: COMPANY OVERVIEW
    • FIGURE 45 ILLUMINA, INC.: COMPANY SNAPSHOT (2023)
    • 4.1.7 HOLOGIC, INC.
    • TABLE 721 HOLOGIC, INC.: COMPANY OVERVIEW
    • FIGURE 46 HOLOGIC, INC.: COMPANY SNAPSHOT (2023)
    • 14.1.8 BIO-RAD LABORATORIES, INC.
    • TABLE 722 BIO-RAD LABORATORIES, INC.: COMPANY OVERVIEW
    • FIGURE 47 BIO-RAD LABORATORIES, INC.: COMPANY SNAPSHOT (2023)
    • 14.1.9 BIOMERIEUX
    • TABLE 723 BIOMERIEUX: COMPANY OVERVIEW
    • FIGURE 48 BIOMERIEUX: COMPANY SNAPSHOT (2023)
    • 14.1.10 SYSMEX CORPORATION
    • TABLE 724 SYSMEX CORPORATION: COMPANY OVERVIEW
    • FIGURE 49 SYSMEX CORPORATION: COMPANY SNAPSHOT (2023)
    • 14.1.11 REVVITY
    • TABLE 725 REVVITY: COMPANY OVERVIEW
    • FIGURE 50 REVVITY: COMPANY SNAPSHOT (2023)
    • 14.1.12 BECTON, DICKINSON AND COMPANY
    • TABLE 726 BECTON, DICKINSON AND COMPANY: COMPANY OVERVIEW
    • FIGURE 51 BECTON, DICKINSON AND COMPANY: COMPANY SNAPSHOT (2023)
    • 14.1.13 AGILENT TECHNOLOGIES, INC.
    • TABLE 727 AGILENT TECHNOLOGIES, INC.: COMPANY OVERVIEW
    • FIGURE 52 AGILENT TECHNOLOGIES, INC.: COMPANY SNAPSHOT (2023)
    • 14.1.14 QIAGEN N.V.
    • TABLE 728 QIAGEN N.V.: COMPANY OVERVIEW
    • FIGURE 53 QIAGEN N.V.: COMPANY SNAPSHOT (2023)
    • 14.1.15 DIASORIN S.P.A.
    • TABLE 729 DIASORIN S.P.A: COMPANY OVERVIEW
    • FIGURE 54 DIASORIN S.P.A: COMPANY SNAPSHOT (2023)
    • 14.1.16 GRIFOLS S.A
    • TABLE 730 GRIFOLS S.A: COMPANY OVERVIEW
    • FIGURE 55 GRIFOLS S.A: COMPANY SNAPSHOT (2023)
    • 14.1.17 WERFEN S.A.
    • TABLE 731 WERFEN S.A: COMPANY OVERVIEW
    • FIGURE 56 WERFEN S.A: COMPANY SNAPSHOT (2023)
    • 14.1.18 QUIDELORTHO CORPORATION
    • TABLE 732 QUIDELORTHO CORPORATION: COMPANY OVERVIEW
    • FIGURE 57 QUIDELORTHO CORPORATION: COMPANY SNAPSHOT (2023)
  • 14.2 OTHER PLAYERS
    • 14.2.1 DEVYSER
    • TABLE 733 DEVYSER: COMPANY OVERVIEW
    • FIGURE 58 DEVYSER: COMPANY SNAPSHOT (2023)
    • 14.2.2 CHEMBIO DIAGNOSTICS, INC.
    • TABLE 734 CHEMBIO DIAGNOSTICS, INC.: COMPANY OVERVIEW
    • FIGURE 59 CHEMBIO DIAGNOSTICS, INC.: COMPANY SNAPSHOT (2022)
    • 14.2.3 SURMODICS, INC.
    • TABLE 735 SURMODICS, INC.: COMPANY OVERVIEW
    • FIGURE 60 SURMODICS, INC.: COMPANY SNAPSHOT (2023)
    • 14.2.4 MENARINI SILICON BIOSYSTEMS
    • TABLE 736 MENARINI SILICON BIOSYSTEMS: COMPANY OVERVIEW
    • 14.2.5 SPEEDX PTY. LTD.
    • TABLE 737 SPEEDX PTY. LTD.: COMPANY OVERVIEW
    • 14.2.6 GENSPEED BIOTECH GMBH
    • TABLE 738 GENSPEED BIOTECH GMBH: COMPANY OVERVIEW
    • 14.2.7 MERCK KGAA
    • TABLE 739 MERCK KGAA: COMPANY OVERVIEW
    • 14.2.8 CARIS LIFE SCIENCES, INC.
    • TABLE 740 CARIS LIFE SCIENCES, INC.: COMPANY OVERVIEW
    • 14.2.9 ARKRAY, INC.
    • TABLE 741 ARKRAY, INC.: COMPANY OVERVIEW
    • 14.2.10 ACCELERATE DIAGNOSTICS, INC.
    • TABLE 742 ACCELERATE DIAGNOSTICS, INC.: COMPANY OVERVIEW
    • 14.2.11 CELLABS
    • TABLE 743 CELLABS: COMPANY OVERVIEW
    • 14.2.12 J. MITRA & CO. PVT. LTD.
    • TABLE 744 MITRA & CO. PVT. LTD.: COMPANY OVERVIEW
    • 14.2.13 EPITOPE DIAGNOSTICS, INC.
    • TABLE 745 EPITOME DIAGNOSTICS, INC.: COMPANY OVERVIEW
    • 14.2.14 BOSTER BIOLOGICAL TECHNOLOGY
    • TABLE 746 BOSTER BIOLOGICAL TECHNOLOGY: COMPANY OVERVIEW
    • 14.2.15 ENZO BIOCHEM, INC.
    • TABLE 747 ENZO BIOCHEM, INC: COMPANY OVERVIEW
    • 14.2.16 GENETIC SIGNATURES
    • TABLE 748 GENETIC SIGNATURES: COMPANY OVERVIEW
    • 14.2.17 SAVYON DIAGNOSTICS LTD.
    • TABLE 749 SAVYON DIAGNOSTICS LTD.: COMPANY OVERVIEW
    • 14.2.18 TRIVITRON HEALTHCARE
    • TABLE 750 TRIVITRON HEALTHCARE: COMPANY OVERVIEW
    • 14.2.19 MDXHEALTH SA
    • TABLE 751 MDXHEALTH SA: COMPANY OVERVIEW
    • 14.2.20 CREATIVE DIAGNOSTICS
    • TABLE 752 CREATIVE DIAGNOSTICS: COMPANY OVERVIEW
    • 14.2.21 INBIOS INTERNATIONAL, INC.
    • TABLE 753 INBIOS INTERNATIONAL, INC.: COMPANY OVERVIEW
    • 14.2.22 MACCURA BIOTECHNOLOGY CO., LTD.
    • TABLE 754 MACCURA BIOTECHNOLOGY CO., LTD.: COMPANY OVERVIEW
    • 14.2.23 VELA DIAGNOSTICS
    • TABLE 755 VELA DIAGNOSTICS: COMPANY OVERVIEW
  • *Details on Business Overview, Products/Solutions/Services Offered, Recent Developments, MnM view (Key strengths/Right to win, Strategic choices made, Weakness/competitive threats)** might not be captured in case of unlisted companies.

15 APPENDIX

  • 15.1 DISCUSSION GUIDE
  • 15.2 KNOWLEDGE STORE: MARKETSANDMARKETS' SUBSCRIPTION PORTAL
  • 15.3 CUSTOMIZATION OPTIONS
  • 15.4 RELATED REPORTS
  • 15.5 AUTHOR DETAILS